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ABSTRACT
NOVEL MASS SPECTROMETRY METHODS FOR THE ANALYSIS OF
COVALENT AND NON-COVALENT PROTEIN STRUCTURES AND THEIR
INFLUENCE ON THE FUNCTIONS OF THERAPEUTIC PROTEINS

MAY 2018

JAKE WALTER APWLOWSKI, B.S., UNIVERSITY OF MASSACHUSETTS
AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST

Directed by: Professor Igor A. Kaltashov

Biotherapeutics consist of biopolymers (proteins, polysaccharides, DNA,
and RNA) that are used to treat a wide range of conditions from cancer to autoimmune
disease to enzyme replacement.

In recent years biotherapeutics have experience

tremendous growth due to advances in technology and our understanding of human
biology. They are very important to modern medicine due to their ability to treat diseases
which are unable to be treated with small molecule-based drugs. Unlike small molecule
drugs which are synthetically produced, biotherapeutics are expressed inside cells.
Produced biotherapeutics are not made up of a single homogenous population but instead
a population of highly similar variants. The source of these variations are enzymatic and
non-enzymatic post-translational modifications. By characterizing these modification, a
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profile is built that links the in vivo response of a drug to its modifications. The complexity
and size of these biopolymers makes their characterization very challenging and demands
the development of robust analytical techniques.
Mass spectrometry- and liquid chromatography-base methods are an integral part
of protein characterization. Mass spectrometry provides accurate mass measurements that
are invaluable for confirming the identity of a protein and any modifications. Additionally,
mass spectrometry is used to assess a protein’s higher order structure.

Liquid

chromatography is a very powerful tool that allows for different post-translational modified
populations of a biotherapeutic sample to separate by their chemical or physical properties.
Separated populations can further be characterized to identify and analyze their chemical
or structural composition. The presented work utilized a blend of mass spectrometry and
liquid chromatography methods to characterize proteins with biotherapeutic potential.
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CHAPTER 1
INTRODUCTION

1.1

Biopharmaceuticals and Their Importance to Modern Medicine
In 1982 from Eli Lily recombinant human insulin was the first marketed

biopharmaceutical leading to a transformation in the pharmaceutical industry.1 Previously,
most commercial drugs consisted of small molecules or biological products purified from
biological sources (i.e. blood). A biopharmaceutical is a protein- or nucleic acid-based
product that is manufactured by any means other than direct extraction from a natural
biological source.2 In recent years, biopharmaceuticals have experienced a rise in market
approvals due to the increased understanding of human and cellular biology and the
underlying mechanisms which lead to diseases.
Perhaps the two most important advances accounting for the rise of
biopharmaceuticals were the developments of recombinant DNA technology and
monoclonal antibody (mAb) production through hybridoma technology.2 The majority of
proteins with therapeutic promise are produced in limiting amounts by the body and are
challenging or impossible to purify economically from biological sources. Fortunately,
recombinant DNA technology, first utilized in 19723,4, permits genes encoding
therapeutically relevant proteins to be expressed in large quantities in cell culture.
Secondly but no less important is the ability to produce monoclonal antibodies (mAb) by
hybridomas technology, developed in 1975.5 A hybridoma is an immortal cell line, created
by the fusion of a B cell and myeloma cell, that produces antibodies with identical structure
and sequence, known as a mAb.6 The ability to produce an almost unlimited amount of an
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identical antibody has made it feasible to treat diseases with mAbs. Examples include
cancer and autoimmune disorders.
Biopharmaceuticals are not limited in their scope to diseases in the body. As the
understanding of human biology moves forward, new treatment opportunities for disease
are possible. In 2016, newly approved biopharmaceuticals covered a diverse range of
ailments that include cancer, autoimmune disorders, psoriasis, and bacterial infections.
This highlights the versatility of biopharmaceuticals as they can be utilized to target and
treat a wide spectrum of diseases.

1.2

Complexity of Biopharmaceuticals
Biopharmaceuticals are produced in cells and are orders of magnitude more

complex than traditional small molecule production.7 Cell lines used for protein expression
include mammalian (Chinese hamster ovary, human embryonic kidney 293, baby hamster
kidney cells, etc.) and non-mammalian (yeast, insect, bacteria, and plant) cell lines.8 A cell
line is chosen depending on the requirements for the biopharmaceutical to be expressed.9
For example, bacterial expression systems benefit from being simple to grow and produce
protein in high yields. However, these expression systems lack the proper glycosylation
enzymes to decorate expressed proteins with human-like glycans.10,11 If human-like
glycans or disulfides are necessary for the biopharmaceutical then mammalian cell lines
are used. Care must still be taken as non-human mammalian cell lines can add

glycans

not found in humans such as N-glycolylneuraminic acid and galactose-a1.3-galactose.8
Due to humans possessing antibodies against these glycans, any biopharmaceutical
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containing these glycans could generate an immune response and thus possibly neutralize
the drug.12
Unlike a small molecule drug whose production is highly controlled, it is
impossible to maintain this same level of control over protein production due to the
complexity inside a cell.7 As a result, a produced therapeutically relevant protein will not
be composed of a single homogeneous protein population but rather a heterogeneous one.
Heterogeneity is due in part to cellular expression, cell culture media, manufacturing
processes, transport, and protein storage.13-18 Additionally, changes in any of these factors
are known to potentially affect the composition of the final product. It is essential to
identify these composition differences and assess they cause a change in efficacy. Even
changes in the headspace of a vial19 or its oxygen level20 are known to alter the composition
of a stored protein drug. These are excellent examples of how even trivial changes in
storage can lead to a different final product. Therefore great effort is exerted to minimize
heterogeneity during production to ensure the safety and efficacy of a biotherapeutic.
As mentioned vide supra a produced biopharmaceutical is not made up of a single
homogenous population but rather a population of highly similar variant forms due to posttranslational modifications (PTMs). The number, range, and variety of these forms are all
dependent on the cell line used, cell culture conditions, and purification processes.7
Variation in the population of highly similar variants is commonly referred to as
microheterogeneity.

As described by the well know biological phrase “structure

determines function”, changes in biopharmaceutical’s structure may adversely affect its
function. Therefore, it is of great importance to characterize and understand at what
thresholds PTMs will change the function of a protein drug.
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1.3

Post-Translational Modifications of Proteins
The majority of heterogeneity in a biopharmaceutical is due to PTMs that occur

inside a cell or during the manufacturing process and storage. PTMs control a protein’s
activity state, cell locations, degradation, and other protein interactions.21 Moreover, PTMs
are not encoded in a protein’s genetic sequence but rather are a product of both enzymatic
and non-enzymatic processes. The lack of ability to directly encode PTMs through a
protein’s DNA sequence makes it difficult to precisely control these modifications and
gives rise to the possibility of a heterogeneous expressed protein. While Table 1.1
describes a small sampling of all the possible PTMs and their effects, there are many PTMs
which makes protein characterization a challenging goal. Therefore, it is important to
detect and quantitate PTMs to ensure that a biopharmaceutical population contains the
correct modifications (i.e. glycosylation) as well as minimal amounts of damaging PTMs
(i.e. oxidation, glycation and deamidation).
Once a biopharmaceutical is characterized, a PTM profile is created to describe all
possible modifications and their effect on a biopharmaceutical. The profile is used as a
standard to compare all future manufactured lots of the biotherapeutic to a quality control
measurement. Additionaly, the PTM profile is linked to the function and efficacy of the
protein drug. Changes to this profile may have significant changes for a biotherapeutic’s
in vivo function.22 Therefore, to ensure different batches of a protein drug will elicit the
same therapeutic response in vivo it is crucial to establish the acceptable presence and range
of PTMs. Also, improvements to a biopharmaceutical’s production and storage can be
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assessed and compared to previously produced protein lots as a way to ensure the drug will
provide the same efficacy.
Table 1.1 List of common PTMs
Type

Description
Enzymatic Post-Translational Modifications

Glycosylation

Phosphorylation

Addition of a glycan chain to an asparagine (N-linked) or a
serine/threonine (O-linked). Glycans are important for proper
protein folding,23 protein stability,24 modulating a protein’s
function,25-30 and cell-cell / protein-protein interaction.31
Phosphate group is added by a kinase to (most commonly) a
serine, threonine, or tyrosine as a way to control the function of
protein in response to a stimuli.32
Non-Enzymatic Post-Translational Modifications

Oxidation

Deamidation

Disulfide Bridge
Glycation

Covalent modification of a protein by a reactive oxygen species.
Addition of an oxygen is known to affect the structure and
function of a protein.33 Oxidation is a sign of protein stress and
may lead to immunogenicity, aggregation, or degradation.34-37
Asparagine (or glutamine) is converted, through a succinimide
intermediate, to aspartic (or glutamic acid) which may affect a
proteins structure and function due to the introduction of a
negative charge (and possible isomerization).38 Can enhance39 or
reduce40 the potency of a biopharmaceutical.
Covalent bond between two cysteines and is important for
maintaining a protein’s structure.41 Disulfide scrambling affects
the proteins structure and may lead to aggregation.42 Trisulfide
formation is also possible and is found in mAbs.43
Hexose is covalently attached to a protein. May affect the efficacy
and stability of a biopharmaceutical.44
Designer Post-Translational Modifications

Pegylation
Drug Conjugates

Addition of a PEG polymer chain to a protein. Increases a
protein’s half-life and solubility.45
Covalent labeling of a protein with a linker and drug. A drug
attached to a mAb can be effectively delivered to its target with an
increased half-life.46
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1.4

Characterization of Biopharmaceuticals
Protein PTMs are complex to understand with regard to the function and stability

of the protein.

Additionally there are hundreds of know PTMs15 which makes

understanding their effects even more challenging requiring a multivariable equation. It is
important to keep in mind that a completely homogenous (structure, sequence, and PTMs)
biopharmaceutical is impossible to produce on a large scale. Fortunately, there are
acceptable ranges in the amount of PTMs in a biopharmaceutical in which they will deliver
a reproducible clinical performance.47 Great effort goes into defining the acceptable range
of PTMs in a biopharmaceutical’s population.

Robust analytical methods must be

implemented to i. identify at what percent of a biopharmaceutical’s population will a PTM
alter its clinical efficacy and ii. accurately quantitate these PTMs to ensure confidence of
the measurements. This will contribute to ensuring that different production lots of a
biopharmaceutical, even with alteration to its PTM profile, will deliver reproducible
results.
Unfortunately, there is not a single analytical tool that can provide all the necessary
information to fully characterize a therapeutic protein. Instead a punctilious suite of
analytical tools is necessary to fully characterize a protein. These tools range in complexity
from simple (UV absorbance) to complicated (hydrogen-deuterium exchange). All these
analytical measurements of a biopharmaceutical are needed to build a profile of a protein.
Once a protein’s profile is established it is used as a standard for the acceptable variations
in the protein’s population. It is with this standard of acceptable ranges for PTMs that the
quality of the protein can be judged
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1.5

Toolbox for Biopharmaceuticals Characterization
There is a wide range of tools varying from spectroscopic- to imaging- to

thermodynamic-based methods that are used for characterizing a biopharmaceutical.
Generally, each tool provides a single straightforward piece of information such as
concentration, percent aggregation, melting point, or hydrodynamic radius. By using all
these measurements, a profile of a biopharmaceutical’s chemical and physical attributes is
generated. Two tools vital for characterizing a protein involve liquid chromatography
(LC)-based, mass spectrometry (MS)-based, or combined LC-MS methods. MS and LC
measurements provide an abundance of information about a protein such as its mass,
heterogeneity, and present PTMs.

1.6

Liquid Chromatography Characterization
It is very rare for a biopharmaceutical to be produced as a single component but

more often as a complex mixture with a variety of components. These complex mixtures
are problematic for protein characterization due to analytical measurements generating
convoluted responses from multicomponent samples. Fortuitously, there are methods
which allow for not only purification but characterization of the therapeutic protein
shrouded in these complex mixtures.
Liquid chromatography is a blanket term used to encompass a diverse group
ofmethods that allow for the separation, identification, and quantitation of similar
components in complex samples. Different types of chromatography separate proteins
based on their size, polarity, and charge among other intrinsic properties. Chromatographic
methods are extremely versatile and an important part of a protein characterization.
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1.6.1

Size Exclusion Chromatography
Size exclusion chromatography (SEC) is unique because that molecules inside the

column do not physically interact with the stationary phase unlike nearly all other types of
chromatography. SEC separates molecules based on their hydrodynamic volume not their
molecular weight as commonly confused (though it is generally a correct assumption that
a larger molecular weight protein will have a larger hydrodynamic volume). Molecules
are able be separated by their hydrodynamic volume by a porous silica bead stationary
phase. If the molecule is small enough to enter these pores the time spent is dependent on
the molecule’s hydrodynamic volume. It is through this process of entering and exiting
pores that molecules are separated from largest to smallest hydrodynamic volumes. An
isocratic elution is used for SEC and the mobile phase can be an aqueous, salt-containing
solution that mimics the ionic strength in the blood (~150mM). The purpose of the mobile
phase is to preserve the structure of the protein in solution and to mask the stationary phase
from non-specific interaction with molecules in solution. Eluting molecules are detected
by UV/VIS absorbance (typically 280nm for aromatic amino acids) but fluorescent or light
scattering detectors may also be used. If MS compatible solutions are used, a mass
spectrometer can be used to further characterize eluting species.
SEC is useful in a variety of ways. One use is to assist with sample purification by
separating the protein(s) of interest from a complex biological mixture of different sized
proteins and molecules. Most commonly SEC is used to detect and estimate aggregation
to ensure the quality of the protein sample. Aggregation of a biopharmaceutical is known
to induce an immune response so it is vital to keep aggregation to a minimum.48
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1.6.2

Reverse Phase Chromatography
Reverse phase chromatography utilizes a non-polar stationary phase to separate

molecules based on their polarity.

The stationary phase consists of a silica bead

functionalized with C4, C8, or C18 alkyl chains. More polar molecules will elute first
followed by less polar. Molecules are eluted with a mobile phase gradient that changes the
mobile phase from a weak polar mobile phase (H2O) to less polar (acetonitrile or methanol)
mobile phase. An optimized gradient is extremely useful because it allows a large number
of different analytes (i.e. proteolytic digest of a protein) to be separated in a single run.
Due to the use of MS friendly solvents, a mass spectrometer can be used as a detector to
help further measure eluting analytes.
Reverse phase chromatography is most commonly used to separate peptides from
a proteolytic digest of a protein.49 Most PTMs will affect the retention of the modified
peptide, as compared to the unmodified peptide, allowing for separation.

A mass

spectrometer measures the mass of eluting peptides to identify its sequence and
modifications that are presentZ. This is extremely useful when characterizing a protein as
it allows a PTM to be identified and localized on a protein.

1.6.3

Ion Exchange Chromatography
Ion exchange chromatography utilizes a charged stationary phase (negative or

positive) to separate analytes based on their charge. A cation exchange column has a
negatively charged stationary phase with the column packing being functionalized with a
carboxylic acid or sulfonic acid. An anion exchange column has a positively charged
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stationary phase with the column packing functionalized with a primary or quaternary
amine. The pI of the analyte and the pH of the mobile phase dictates which type of ion
exchange column is used. Molecules are eluted with a mobile phase gradient where the
pH is adjusted or the salt concentration is increased. If MS friendly solvents are used a
mass spectrometer can be used to measure eluting analytes. Ion exchange chromatography
is very powerful because of its ability to take advantage of the charge heterogeneity in
protein samples.

1.6.4

Other Types of Chromatography
Polar compounds (i.e. glycans and some peptides) are weakly retained in reverse

phase columns, eluting at or close to the void volume and are thus unable to be effectively
separated. Hydrophilic interaction liquid chromatography (HILIC) offers an alternative to
reverse phase chromatography for separation of polar samples.50 Glycan characterization
is an important part of drug discovery and HILIC is a great tool for separating glycan
chains.51 Additionaly, due to HILIC’s use of MS-friendly solutions, eluting samples can
be analyzed online via MS.
Affinity chromatography is generally used as a purification method to remove a
biopolymer of interest from a complex solution but has some application as a
characterization tool. A protein G, protein A and FcRn affinity column all can be used to
detect and measure oxidation of a mAb in its Fc domain.52-54 Oxidation of two conserved
methionines (252,428) at the CH2-CH3 interface negatively affects the half-life of a
mAb.55 Therefore, it is vital to ensure there is not significant amount of a mAb oxidized
at these methionines as it will affect the therapeutic efficacy of a mAb.
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Affinity

chromatography offers the unique ability to specifically target and separate a specific
protein from a complex mixture.

1.7

Mass Spectrometry Characterization
Mass spectrometry (MS) is a powerful characterization tool that has experienced

rapid growth in recent years due to both improved hardware and software. No other
technique offers the ability to accurately and precisely measure the mass of a biopolymer.
Electrospray ionization (ESI) MS and matrix assisted laser desorption ionization (MALDI)
are soft ionization techniques that were a fundamental part to the rise of MS. Both
ionization techniques can preserve covalent and non-covalent bonds during ionization with
little to no induced fragmentation making them ideal for measuring biopolymers.
MS is an excellent tool for measuring the primary structure of a biopolymer. If the
sequence of a biopolymer is known then a theoretical mass can be calculated and compared
against the experimentally measured mass.

This is an important part of protein

identification and characterization since it confirms that the correct protein has been
produced as well as providing an assessment of its quality and purity. Additionaly, PTMs
can be identified by measuring mass shifts in comparison to an unmodified protein. While
the presence or absence of a PTM is important information, the location of the PTM is just
as significant. Tandem MS measurements localize PTMs on a protein by inducing
fragmentation of a polypeptide backbone in the gas phase. Produced fragments are
measured and provide more localized data of to identify the location of the PTM. Ideally
this is performed at the whole protein level, known as top-down MS, but for proteins over
30 kDa56 it becomes nearly impossible to achieve the necessary resolution for PTM
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localization.

For large proteins, a bottom-up or middle-down approach must be

implemented that typically involve enzymatic digestion of a protein. Using a reverse phase
column, digested protein fragments or peptides are separated and eluting molecules are
measured by tandem MS. These measurements are indispensable for characterizing the
primary structure and PTMs of a biopharmaceutical.
In addition to measuring the mass of a biopolymer to confirm its identity and
associated PTMs, mass spectrometry is also used to for higher order structure
measurements. Two methods, fast photochemical oxidation of proteins (FPOP) and
hydrogen deuterium exchange (HDX), utilize covalent labeling to measure the higher order
structure and dynamics of a protein in solution. FPOP covalently labels solvent exposed
amino acid residues by oxidation with hydroxyl radicals produced by photolysis of H2O2.57
Oxidation is detected by MS in a bottom-up or top-down approach depending on the
complexity and size of the protein. HDX exchanges the backbone amide hydrogen of a
protein with deuterium using a D2O solution. Unprotected (i.e. not participating in a
hydrogen bond) or solvent exposed amide hydrogens will quickly exchange with deuterium
while protected regions will undergo a slower exchange. Mass shift from deuterium
labeling are measured by MS, usually in a bottom-up approach. Both FPOP and HDX
provide data about the structure and dynamics of a protein in solution by the distribution
of their covalent labels. Changes to a protein’s structure due to a PTM or solvent conditions
can be measured to elucidate their effect to a protein’s higher order structure. These
measurements when combined with NMR or x-ray crystallography provide in depth
information about a protein’s conformation and dynamics in solution.
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1.7.1

Native MS
Native MS is an excellent tool for studying a protein’s higher order structure.

Unlike traditional MS measurements, native MS utilizes near native solutions (150mM
ammonium acetate) that preserve the native structure of a protein in solution. ESI MS, first
used in the 1980s,58 is a soft ionization technique that allows a protein remain folded during
the ionization process.59 The combination of a gentle ionization technique and a native
solution allows for non-covalent interactions and protein complexes to be preserved for
MS measurement. From these measurements, some structural information can be extracted
based on the charge state distribution. Unlike traditional MS which uses solvents that
denature a protein, native MS preserves the structure thus making it more compact in the
gas phase. This more compact molecule carries less charge due to a decrease in available
surface area for protonation and a narrower charge state distribution.60 If a portion of the
protein is unfolded in solution a bimodal charge state distribution will be observed
indicating as both unfolded and folded species are present in solution. In the case of
quaternary structures the measured mass can help identify components which make up the
multimeric protein structure. Native MS is a valuable tool which allows the native fold of
a protein to be preserved during measurement to provide structural and composition
information.

1.8

Monoclonal Antibodies
Immuglobulins possess properties that make them excellent candidates as

biopharmaceuticals. These properties include robustness to harsh conditions, a long halflife, a versatile mechanism of action, and possible immune system activation.
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An

immuglobulin is a heterodimeric protein composed of two light (L) and heavy (H) chains
as shown in Figure 1.1. An immuglobulin is divided into two domains that are a fragment
antigen binding (Fab) and fragment crystallizable (Fc) domain. As the name suggests, the
Fab domain is responsible for binding its cognate target. The Fc domain is responsible for
a mAb’s effector functions that includes complement activation, antibody-dependent
cellular cytotoxicity, antibody-dependent phagocytosis, degranulation, cytokine release,
and inhibition of cell activities among other functions.61,62 The majority of these effector
functions are mediated through binding
of Fc gamma receptors (FcgRs) present
on immune system related cells. How
the adaptive immune system responds to
an antigen depends on the bound
antibody and its associated effector
functions.
There

are

five

classes

of

immuglobulins IgA, IgD, IgE, IgG, and
Figure 1.1 Two H (green) and L (blue)
chains make up an immuglobulin. Colored
IgM that each serve unique functions
spheres represent glycan chains.
PDB: 1HZH
inside the body. All currently approved clinical mAbs are based on the IgG template due
it its favorable biological qualities.63,64 IgG is glycosylated in its Fc domain on each of its
H chains at Asn297. Both glycan chains help provide structure to the Fc domain and the
glycan composition is known to affect the effector functions of the IgG.61,65-70
While all therapeutic mAbs bind their target through the Fab domain, a mAb’s
specific mechanism of action is quite diverse and includes: drug delivery, target
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neutralization, cell destruction, and imaging. Depending on the mechanism of action of a
mAb the effector function needs to be tailored to ensure the correct in vivo response. One
option to tailor the effector function of aa mAb is through its glycan chain.62 For example,
if the mechanism of action is cell destruction then an elevated antibody dependent cellular
cytotoxicity would be beneficial. An afucosylated mAb is known to exhibit a much greater
antibody dependent cellular cytotoxicity thus making it more effective at destroying its
cellular target.25 If the mAb is to be strictly a drug delivery vehicle or is being used for
imaging, an immune response may be unnecessary or even detrimental to its target.
Removal of the glycan chain offers an attractive option to abrogate a mAb’s effector
function65,66 and thus preventing an immune response to its target. It is clear that all these
factors need to be considered when producing the final product and necessitates proper
characterization of these mAbs to elucidate their in vivo properties.

1.9

Transferrin
There are several plasma proteins, other than antibodies, that have

biopharmaceutical potential. Transferrin (Tf) is an excellent candidate due to favorable in
vivo qualities. The most important quality (in terms of its usefulness as a protein drug) of
Tf is its ability to cross the blood brain barrier. Tf offers the ability to transport attached
drugs to targets in the brain or central nervous system71-73 Unlike a mAb which directly
affects its target, Tf may act as a passive carrier for an attached drug. Additionally,
quantitative information about the drug distribution can be measured by taking advantage
of Tf’s ability to bind metals other than iron (i.e. indium).71 The ability for Tf to cross the
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blood brain barrier and bind metals other than iron gives it great potential as a
biopharmaceutical.

1.9.1

The Role of Transferrin in Iron Homeostasis
Tf is not only has potential as a biopharmaceutical but has an important biological

role in the body as the iron transporter in the serum. Iron is the 4th most abundant element
in the earth’s crust74 and is essential to almost every living organism due to its intrinsic
redox properties. During the appearance of the first single cell organisms the Earth’s
atmosphere was composed of very little O2.75 The lack of atmospheric oxygen provided
cells with an abundance of readily available Fe2+ thus establishing a foothold in biological
processes.75 As the Earth’s atmosphere changed to high oxygen conditions iron became
more scarce due to Fe3+ forming insoluble iron oxides. This necessitated that organisms to
develop strategies to capture Fe3+ which is extremely insoluble (Ksp 1.6x10-39) in aqueous
solutions.

Furthermore, the same attractive redox properties of iron for biological

processes makes them potentially dangerous. Fe2+ reduces O2 and can lead to a hydroxyl
radical which is extremely damaging to cells.75 Additionaly, due to iron being a scarce
essential resource for invading pathogens it is imperative to sequester iron as an immune
system strategy. Iron must be tightly controlled to help prevent damage by free radicals or
invading pathogens.
Tf is a key player in iron homeostasis inside the body. It is an 80kDa bilobal
glycoprotein and the major iron transport protein inside the blood. Each lobe of Tf (Figure
1.2) is capable of binding Fe3+ tightly (Kd ~1022) but reversibly.76 Iron is coordinated by
two tyrosines, one histidine, and one aspartic acid (Tyr95, Tyr188, Asp63, and His249 in

16

the N-lobe and Tyr426, Tyr517,
Asp392, and His585 in the C-lobe,
respectively) in each lobe.

A

synergistic anion, usually carbonate,
is required to complete iron binding
in transferrin. However, oxalate can
also coordinate with Fe in Tf and is
Figure 1.2 Diferric Tf with two irons (red)
bound. PDB: 1HZH

known to prevent the release of Fe
inside of cells. Iron is delivered to

cells through Tf interacting with a Tf receptor to enter the cell. Once inside an endosome,
the pH is lowered to assist with iron release after which the Tf-Tf receptor complex is
returned to the cell surface.76 Disruptions to the ability of Tf to bind and release iron is
troublesome to iron homeostasis in the body.

1.10

Objectives
The complexity of biopharmaceuticals necessitates the need for robust analytical

methods to characterize biopolymers and their PTMs. It is through PTMs that a protein’s
function is defined and allows for proteins to be adaptable with their function in the body.
Careful measurements are needed to link the presence and amount of PTMs with a protein’s
in vivo function. LC- and MS-based methods are a valuable tool for characterizing
biopharmaceuticals by providing a wealth of information about a protein’s sequence,
structure, and modifications. The work presented in the following chapters discuss the
development of LC and MS methods to characterize proteins with biopharmaceutical value
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(mAb and Tf). Specifically, the chapters discuss: i. development of a method to extract Tf
from a clinical sample (serum) and utilizing native MS to determine its metal and
synergistic anion composition, ii. Modification of a mAb’s glycan chain and the effect on
its biophysical properties and effector function and, iii development of a novel cross path
reactive chromatography method for in column reduction or oxidation of disulfidecontaining proteins.
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CHAPTER 2
ASSESSING THE IRON DELIVERY EFFICACY OF TRANSFERRIN IN
CLINICAL SAMPLES BY NATIVE ELECTROSPRAY IONIZATION MASS
SPECTROMETRY
This chapter has been adapted from a paper published as: Pawlowski, J. W., Kellicker,
N., Bobst, C. E. & Kaltashov, I. A. Assessing the iron delivery efficacy of transferrin in
clinical samples by native electrospray ionization mass spectrometry. Analyst 141, 853861, doi:10.1039/C5AN02159F (2016).

2.1

Abstract
Serum transferrin is a key player in iron homeostasis, and its ability to deliver iron

to cells via the endosomal pathway critically depends on the presence of carbonate that
binds this protein synergistically with ferric ion. Oxalate is another ubiquitous anionic
species that can act as a synergistic anion, and in fact its interaction with transferrin is
notably stronger compared to carbonate, preventing the protein from releasing the metal in
the endosomal environment. While this raises concerns that high oxalate levels in plasma
may interfere with iron delivery to tissues, concentration of free oxalate in blood appears
to be a poor predictor of impeded availability of iron, as previous studies showed that it
cannot displace carbonate from ferro-transferrin on a physiologically relevant time scale
under the conditions mimicking plasma. In this work we present a new method that allows
different forms of ferro-transferrin (carbonate- vs oxalate-bound) to be distinguished from
each other by removing this protein from plasma without altering the composition of the
protein/metal/synergistic anion complexes, and determining their accurate masses using
native electrospray ionization mass spectrometry (ESI MS). The new method has been
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validated using a mixture of recombinant proteins, followed by its application to the
analysis of clinical samples of human plasma, demonstrating that native ESI MS can be
used in clinical analysis.

2.2

Introduction
Iron is an essential element that is required for nearly all living organisms. There

are 3-5 grams of iron present in a healthy adult body with over 2 grams found in
hemoglobin of erythrocytes.152 Despite the attention paid in the field of nutraceuticals to
iron dietary supplements, the majority of iron circulating in plasma is actually recycled
from reticuloendothelial macrophages through the degradation of erythrocytes as well as
other cells.212 Although it is one of the most abundant elements in the Earth’s crust, iron
bioavailability is limited due to the extremely low solubility of the ferric ion (Fe3+, the
predominant form under aerobic conditions), forcing all living organisms to devise various
strategies to solubilize this element. In vertebrates, this problem is solved using proteins
that bind iron tightly while in circulation and release it in cells via receptor-mediated
endocytosis.85,123 Human serum transferrin (Tf), a protein intimately involved in iron
homeostasis, transports iron to cells that need this metal and express the Tf receptor on
their surface; meanwhile, Tf sequesters iron from pathogens that also require this element
for growth and proliferation.
Tf is an 80 kDa bilobal glycoprotein, with each lobe capable of binding Fe3+ strongly (Kd
~ 1022) but reversibly at physiological pH (7.4).120 Following its association with the Tf
receptor at the cell surface, Tf is internalized and releases iron under the mildly acidic
conditions of the endosome, before being recycled back to the cell surface and released to
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circulation for another cycle of iron acquisition and delivery.2 An intriguing feature of Tf
(shared across the entire family of Tf-related proteins, including lactoferrin and
ovotransferrin) is the presence of a synergistic anion (typically carbonate, CO32-) in the
Fe3+/Tf complex, which is required to complete the metal’s coordination sphere124 (see
Supplementary Material for more detail). Oxalate (C2O42-) is another ubiquitous anionic
species capable of acting as a synergistic anion.65 While its concentration in serum (10-30
µM26) is significantly lower compared to the total pool of carbonate (20-30 mM26), it has
significantly higher Tf affinity.175
The documented ability of oxalate to prevent iron release from Tf under endosomal
conditions67 has led to concerns that it may interfere with iron trafficking by inhibiting its
release from Tf inside the endosome and, therefore, deprive cells of this essential nutrient
even though there is no iron deficiency in the diet or circulation. Under these circumstances
the clinical symptoms of anaemia would not correlate with the results of laboratory testing,
which commonly relies on total iron and protein-bound iron as the biomarkers. While
anaemia is involved in the etiology of a range of pathologies,117 iron deficiency is
particularly devastating for the function of the central nervous system, adversely affecting
inter alia sleep, attention, and cognitive development.103,149,183 In the past decade several
studies have reported an increased prevalence of iron deficiency in autistic children,20,40,41
suggesting the involvement of anaemia in the etiology of autism spectrum disorders,
although more recent studies failed to confirm this correlation.164
One possible explanation for the lack of an obvious correlation between iron status and the
occurrence/severity of autism is based on a recent observation by Konstantynowicz et al.
of a three-fold greater plasma oxalate levels in autistic children compared to their
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symptom-free peers.104 Oxalate replacing Tf-bound carbonate is likely to disturb iron
homeostasis by inhibiting metal release in the endosome (Figure 2.1). However, Mason et
al. have pointed out that the serum level of oxalate could be a poor predictor of the
disturbed iron homeostasis, as this anion fails to displace carbonate from transferrin on a
physiologically relevant time scale in solution that has the same pH and ionic strength as
blood serum.120 While it is possible that oxalate may easily out-compete carbonate during
the iron loading of transferrin, especially under mildly acidic conditions, the molecular
mechanisms of iron loading remain a subject of debate, and it remains unclear if there is
correlation between serum oxalate levels and the presence of oxalate as a synergistic anion
in circulating Fe2Tf.
Clearly, a meaningful diagnostic test in this case should specifically focus on the
relative amounts of oxalate and carbonate bound to Tf (rather than on the total oxalate
concentration in the plasma). Together with the total amount of Tf-bound iron, this number
should provide a true measure of Tf potency vis-a-vis iron delivery to cells. While the
existing analytical protocols cannot accomplish this task, native electrospray ionization
mass spectrometry (ESI MS) has been shown in the past to be a powerful tool capable of
determining the composition of the protein/metal complexes.65,145,221,225 However, such
measurements are always carried out in vitro using solvent systems compatible with the
ESI process; to the best of our knowledge, no reports have been published on applying
native ESI MS to characterize metalloproteins in clinical samples. Another complication
arises from the very small difference between the two synergistic anions (28 Da, which is
less than 0.04% of the mass of Tf). Although modern mass spectrometry allows even
smaller mass differences to be measured for polypeptide ions, these measurements are
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typically carried out under denaturing conditions; the gentle nature of native ESI MS
typically results in formation of multiple adducts, leading to ion peak broadening and
making high-resolution and high-accuracy mass measurements extremely challenging.118
In this work we present a new method for the analysis of clinical blood samples that allows
the composition of the endogenous ternary complexes (Fe·CO32-/C2O42-)2Tf to be probed
using a combination of size exclusion and albumin-depletion chromatographic separations
and native ESI MS detection. The new method is tested with a mixture of recombinant
proteins of known CO32-/C2O42- composition and then applied to clinical samples. The
technique is ready to be used in clinical studies, to search for a correlation between autism
and iron deprivation caused by Tf-bound oxalate.

2.3

Experimental
Materials. Recombinant human Tf used in this work was a generous gift from Prof.

Anne B. Mason (University of Vermont College of Medicine, Burlington, VT, USA), and
the glycosylated form of human Tf was purchased from Sigma-Aldrich Chemical Company
(St. Louis, MO, USA). Clinical samples of human serum from anonymous volunteers were
provided by Prof. Barry Braun (University of Massachusetts-Amherst, Department of
Kinesiology). Amicon Ultracel membrane microconcentrator devices (10 kDa molecular
weight cut-off) were purchased from EMD Millipore (Billerica, MA, USA). Cibacron
F3GA resin was purchased from Pall Corporation (Westborough, MA, USA). Oxalate,
EDTA, ammonium acetate, and formic acid were purchased from Sigma-Aldrich Chemical
Company (St. Louis, MO, USA); all other solvents and buffers were of analytical grade or
higher.
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Preparation of Tf Standards. The apo- (iron-free) form of Tf was prepared by
lowering the pH of Tf solution in 150 mM ammonium acetate to 4.5, followed by addition
of EDTA (to a final concentration of 10 mM). This solution was incubated at room
temperature for an hour, and then buffer exchanged repeatedly to a 150 mM ammonium
acetate solution containing 10 mM EDTA with pH adjusted to 5.5 using a
microconcentrator. During the final step the Tf solution was buffer exchanged to 150 mM
ammonium acetate with pH adjusted to 6.8. The complete removal of both metal and
synergistic anion from the protein was verified by native ESI MS (vide infra). The oxalatebound form of holo-Tf, (Fe3+·C2O42-)2Tf, was prepared by adding oxalic acid to the holoTf solution (dissolved in 150 mM ammonium acetate) to a final concentration of 10 mM
followed by adjusting the pH down to 5.0 with acetic acid and one-hour incubation at room
temperature prior to raising the pH back up to 6.8 with ammonium hydroxide. Excess of
carbonate, bicarbonate and oxalate was removed from the protein solution by repeated
buffer-exchange to 150mM ammonium acetate (pH 6.8). The composition of the
protein/metal/synergistic anion complex in the final solution was confirmed as
(Fe3+·C2O42-)2Tf by native ESI MS (vide infra).
Tf Purification from Clinical Samples. Tf was extracted from the clinical serum
samples

using

a

two-dimensional

chromatography

comprising

size

exclusion

chromatography (SEC) and affinity chromatography (albumin depletion). Briefly, a 125
µL aliquot of unprocessed serum was injected onto a Superose 12 SEC column using a 150
mM solution of ammonium acetate (pH 6.8) as a mobile phase and a 0.45 mL/min flow
rate. Absorption at 470 nm was used to identify eluting Tf. Multiple injections were used
to collect Tf-containing fractions, which were subsequently pooled. Removal of serum
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albumin from these pooled fractions was carried out using a home-made gravity-driven
affinity column packed with Cibacron F3GA resin (BDR). A step gradient was used to
allow hTf to be eluted from the column while retaining HSA. Three buffers were used for
the step gradient: a no-salt buffer (pH 6.8, 150 mM ammonium acetate), a low salt buffer
(pH 6.8, 0.25 M NaCl, 150 mM ammonium acetate), and a high salt buffer (pH 6.8, 2 M
NaCl, 150 mM ammonium acetate). All holo-Tf eluted during the no-salt step, which was
collected and buffer-exchanged to 150 mM ammonium acetate (pH 6.8) using a
microconcentrator (vide supra).
Native ESI MS Analyses. All mass spectral data were acquired with a SolariX 7T
Fourier transform ion cyclotron resonance (FT ICR) mass spectrometer (Bruker Daltonics,
Billerica, MA, USA). All samples were directly infused at a flow rate of 3 µL/min. A 4500
V capillary voltage was used for all measurements. The dry gas was set to a flow of 4.6
L/min and a temperature of 200oC. Each measurement had a 0.52 second transient time
and a 32,000-point time-domain. All spectra were acquired in a 3,500-5,000 m/z range with
400 scans were averaged for each measurement to achieve adequate signal-to-noise ratio.
The ESI source parameters were adjusted to minimize collisional activation in the ESI
interface region in order to preserve the integrity of the protein/metal/synergistic anion
complexes. Reference mass spectra of metal- and synergistic anion-free protein for each
sample were acquired by lowering the pH of the protein solution to 3.7. Data analysis was
performed using Compass Data Analysis software (Bruker Daltonics). Generally, the m/z
value was assigned for each Tf charge state peak observed. Mass shifts were calculated by
subtracting m/z values, of the same charge state, and multiplying the difference by the
charge state. Experimentally determined mass shifts were compared to expected calculated
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values in order to assign the synergistic anion and metal composition (an example of using
this procedure is shown in Supplementary Material).

2.4

Results and Discussion
The unequivocal proof that oxalate does disturb iron homeostasis in a specific

patient can only be provided by measuring the fraction of Tf molecules in circulation in
which carbonate is replaced with oxalate. Existing methods that measure plasma oxalate
do not provide such information; however, the ligand composition of Tf/metal complexes
can be probed by native ESI MS in vitro.221 In the past, we used this technique to determine
the presence of oxalate as a synergistic ion in a fragment of Tf molecule (its N-lobe),65 but
the subsequent attempts to extend this method to the full-length protein produced mixed
results, as the broad shape of the mass spectral peaks typical of native ESI MS prevented
us from being able to make unequivocal assignments, while collisional desolvation led to
facile dissociation of the synergistic anion form the protein prior to the mass
measurement.66,225 Another problem related to the use of native ESI MS for the analysis of
a clinical sample is the presence of significant amounts of strong electrolytes (e.g., NaCl),
which are incompatible with the ESI process and must be removed/replaced with volatile
electrolytes (e.g., CH3CO2NH4) during the sample preparation step. The problem here lies
with the possibility of altering the composition of the Tf/metal/synergistic anion complexes
prior to MS analysis, which would obviously render the results of the testing meaningless.
In order to circumvent these problems, we initially worked with recombinant and
commercially available protein molecules to explore the utility of thermal desolvation as a
tool capable of removing non-specific adducts from the Tf/metal/synergistic anion
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complexes in the ESI interface without altering their composition. This was followed by
designing a protocol of Tf extraction from clinical samples and placing them in “ESIfriendly” solutions without altering the composition of the Tf/metal/synergistic anion
complexes. The absence of any alteration of these complexes’ make-up (either due to
loss/exchange of synergistic anions or due to a bias introduced by the procedure that would
preferentially extract one particular form of the protein at the expense of others) was
verified using a mixture of (Fe3+·CO32-)2·Tf , (Fe3+·CO32-)·(Fe3+·C2O42-)·Tf and
(Fe3+·C2O42-)2Tf complexes that were prepared using recombinant human Tf. Finally, the
procedure was applied to test several anonymized blood samples for the presence of oxalate
bound to serum Tf. Intriguingly, while most of the analyzed samples contained only
carbonate-bound Tf, one contained (Fe3+·C2O42-)2Tf as a major component with a mixed
complex (Fe3+·CO32-)·(Fe3+·C2O42-)·Tf also present (no (Fe3+·CO32-)2·Tf signal was
detected in this anomalous sample).
Native ESI MS can make a distinction between the carbonate- and oxalate-bound
forms of Fe2Tf. The mass difference between carbonate and oxalate dianions is 28 Da; this
number dictates the minimal level of precision that must be attained in the protein mass
measurements in order for the meaningful analysis of the composition of serum transferrin
to be carried out. The ability to resolve a mass difference of 28 Da would allow a distinction
to be made e.g. between a mixed complex (Fe3+·CO32-)·(Fe3+·C2O42-)Tf and the carbonatebound form (Fe3+·CO32-)2·Tf). Although this mass difference corresponds to < 0.04% of
the total protein mass, the resolving power of many modern MS instruments allows such
measurements to be readily made. One complication that arises in our particular case is
that such measurements must be carried out under the so-called native conditions, which
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presents two challenges. First, protein ions accumulate relatively low number of charges
in native ESI MS, giving rise to the ionic signal in the high m/z range (> 3,500 for Tf94),
where most instruments typically have sub-optimal resolution. Second, the gentle nature
of native ESI MS results in production of multiple adducts, leading to broadening of ion
peaks in mass spectra, which affects both the accuracy of the mass measurements and the
ability to resolve closely spaced ion peaks. While mild collisional activation of ions
representing protein complexes frequently enhances the ionic peak shapes (via adduct
dissociation), it also leads to partial dissociation of non-covalent assemblies in the gas
phase.63,111 In the case of Tf, it results in facile removal of the synergistic anion from the
protein,65,66 which obviously invalidates the measurements aimed at determining the
composition of Tf/ferric ion/synergistic anion complexes.
Recently we reported that such complexes exhibit surprising stability when
subjected to thermal desolvation, even though the adduct ions dissociate readily, allowing
high mass accuracy measurements to be made.120 Figure 2.2 shows native ESI mass spectra
of recombinant human Tf reconstituted with carbonate and oxalate, where both carbonateand oxalate-bound forms of Tf can be readily identified based on their masses. The
identification becomes particularly straightforward when the ligand composition of the
complex is determined based on the mass difference between the complex ion and the apoTf ion (228.8 Da and 287.2 Da for the peaks shown in Figure 2.2); the theoretical mass
differences are 229.7 Da for the carbonate-bound form (calculated as a mass of 2Fe3+ +
2CO32- - 2H+) and 285.8 Da (2Fe3+ + 2 C2O42- - 2H+) for the oxalate-bound Tf.

Extraction of Tf from serum for the synergistic anion analysis. Although native MS
with thermal ion desolvation in the ESI interface does allow the distinction to be made
36

between the carbonate- and oxalate-bound Tf, it is important to remember that the mass
spectra shown in Figure 2.2 were acquired using a sample prepared with volatile
electrolytes (ammonium acetate). Direct analysis of a serum sample by ESI MS generates
abundant, but unresolved (and, therefore, analytically meaningless) ion signal due to the
presence of (i) multiple protein species and (ii) non-volatile electrolytes leading to facile
cluster ion and adduct ion formation. To circumvent this problem, we ran the serum sample
through a size exclusion column using an “electrospray-friendly” solvent system (150 mM
ammonium acetate) whose ionic strength and pH are close to those of serum. While the
protein signal spans over a significant time range (Figure 2.3), only three chromatographic
bands showed strong absorbance at 470 nm (characteristic of the holo-form of Tf). The
elution time of the second band (9 min) was consistent with the molecular weight of Tf;
indeed, when this fraction was collected and analyzed by MS, Tf could be readily detected
(see inset in Figure 2.3). Unfortunately, this fraction also contained a significant amount
of albumin, whose molecular weight is close to that of Tf, but abundance in serum is an
order of magnitude higher. Ionic peaks representing these two proteins had significant
overlap, which made accurate mass measurement of Tf ions (and identification of the
synergistic anion) very challenging. Albumin depletion is a common task in blood
proteomic analyses, and is usually accomplished by running the sample through an affinity
column containing antibodies to the fourteen most abundant plasma proteins.79
Unfortunately, Tf is one of the proteins depleted using these commercial kits, making it
necessary to seek alternative ways of albumin depletion. We accomplished this using blue
dye resin (BDR), which has a high affinity to albumin.187 Injecting the Tf/albumin
containing SEC fraction through the BDR column allowed holo-Tf to elute at low ionic
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strength while albumin was retained and could only be eluted under high salt conditions.
Ammonium acetate was used as a salt in the affinity separation (or, more correctly,
depletion) step, allowing all eluting fractions to be analyzed by native ESI MS without
additional sample work-up.
The combination of SEC fractionation with albumin depletion produces a serum Tf
sample suitable for the analysis of its composition vis-a-vis the synergistic anion by native
ESI MS; however, it also introduces the possibility that the ratio of carbonate- vs. oxalatebound forms of Tf is altered prior to MS analyses. This can occur through two possible
mechanisms. First, it is not inconceivable that the recoveries of the two forms of Tf could
be different from each other; in this case, the extraction procedure would introduce a bias.
Second, both apo-Tf and mono-ferric Tf may acquire iron during the extraction and
albumin depletion steps if the metal is present in the soluble form e.g. in BDR. Should this
occur, a bias would be introduced favouring the carbonated form of holo-Tf (although
neither oxalate nor carbonate salts were used in preparation of solvents used for protein
extraction and albumin depletion, ambient CO2 is likely to contribute to formation of
carbonate in solution which can be utilized as a synergistic anion by Tf upon metal
binding). In order to prove that no bias is introduced prior to the MS measurements by
either the SEC fractionation or the albumin depletion step, a mixture of the three forms of
diferric Tf (carbonate-bound form, (Fe3+·CO32-)2·Tf; the oxalate-bound form, (Fe3+·C2O42)2·Tf; and the mixed form (Fe3+·CO32-)·(Fe3+·C2O42-)·Tf) was prepared and subjected to
the established Tf extraction workflow prior to native ESI MS (Figure 2.4). Comparison
of the protein peak profiles in each case before and after the procedure provided
unequivocal evidence that no detectable bias is introduced by either the SEC fractionation
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or the albumin depletion step. Additionally, the apo-form of Tf was tested for its ability to
scavenge for iron (which could conceivably be present in either SEC or BDR columns due
to contamination or carry-over) during either of the two sample preparation steps. Once
again, the result of this study was negative, as neither step lead to detectable acquisition of
iron by the metal-free form of the protein (Figure 2.5).
Synergistic anions bound to endogenous Tf in human blood: analysis of clinical
samples. Once the procedure for Tf extraction from serum followed by identification and
quantitation of synergistic anions had been validated, it was applied to the analysis of
clinical samples. One significant difference between the recombinant proteins discussed
above and endogenous Tf encountered in plasma is that the protein mass of the latter may
differ from the mass based on the published wild-type sequence and glycosylation pattern.
Tf glycosylation is known to be affected by several disorders (with alcoholism being
perhaps the best known,11 but certainly not the only example).231 Glycosylation is an
enzymatic post-translational modification (PTM) that generally leads to heterogeneous
protein populations. Tf is rather unusual in that regard, as it exhibits surprising level of
homogeneity with over 80% of all protein molecules being modified with two fully
sialylated biantennary glycan chains,213 while other glycosylation patterns make minor
contributions213,231 Mass profiling of both commercial Tf and Tf extracted from patients’
blood confirms the paucity of minor Tf glycoforms (see Supplementary Material for more
detail). However, the protein mass can also be affected by various non-enzymatic posttranslational modifications as a result of stress or protein aging; the presence of Tf mutants
in some patients cannot be excluded either. Therefore, confident identification of the
synergistic anions bound to Tf in vivo would not be possible without the knowledge of the
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apo-Tf mass in each patient. To obtain this information, we carried out the analysis of each
serum sample in two steps. First, following the SEC fraction collection and albumin
depletion on the BDR column, the sample was analyzed by native ESI MS, yielding the
total mass of the protein/metal/synergistic anion complex. After that, the sample was
quickly acidified, causing the complex to dissociate, and the mass spectrum was recorded,
yielding the mass of the endogenous protein in its apo-form. This allowed the total mass
of the ligands (metal and synergistic anion) to be calculated as a mass difference between
the two forms of the protein (Figure 2.6).
Five out of six anonymized blood samples revealed nearly identical MS patterns;
one example is presented in Figure 2.6A. The extracted metal-bound Tf population
consists of both mono-ferric and di-ferric species, each utilizing carbonate as a synergistic
anion. The presence of the mono-ferric form of Tf is consistent with the known pattern of
Tf metal loading in healthy subjects, which typically contains a distribution of apo-, monoferric and di-ferric protein species. Interestingly, one of the patients exhibited a very
different metal loading pattern, with only di-ferric protein species present in the sample.
The two distinct peaks present in the mass spectrum (Figure 2.6B) correspond to the
oxalate-bound form (Fe3+·C2O42-)2·Tf and to the mixed form (Fe3+·CO32-)·(Fe3+·C2O42)·Tf.
The fact that the oxalate-bound Tf species were detected in one of the clinical
samples is exciting, as it clearly signals the ability of oxalate to act as a synergistic anion
in vivo, and not just in vitro, as had been previously demonstrated.121 We note that this
anomalous clinical sample did not reveal the presence of mono-ferric forms of Tf, which
may be indirect evidence of the inhibition of iron release in vivo by oxalate acting as a
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synergistic anion. Indeed, the inability of Tf to unload iron in the endosome coupled with
continuous iron uptake would result in complete saturation of the protein with the metal.
Since the focus of this work was on method development, and we did not have access to
the patients’ medical records, it is impossible to draw any definitive conclusions regarding
the interference of Tf-bound oxalate and iron homeostasis. It is clear, however, that oxalate
can act as a synergistic anion, likely interfering with the iron delivery to cells. The ability
to differentiate between carbonate- and oxalate-bound Tf in clinical samples will provide
clinicians with a powerful tool that can be used to establish an actual role of oxalate in
symptomatic iron deprivation, as well as in the etiology of neuropathologies caused by
insufficient supply of iron to the brain during its development.
So far, in the majority of cases autism has eluded attempts to discover its genetic
origins,194 hinting at the importance of complex gene-environment interactions in the
etiology of this disease.25 Extensive efforts to identify metabolic biomarkers of autism have
also met only with limited success.140,191,206 Nevertheless, a relentless pursuit of autism
biomarkers continues with the ultimate goal of improving both diagnosis of the disease and
evaluation of the effectiveness of therapeutic interventions, and currently the most
promising strategies appear to be those integrating Omics-based approaches and clinical
data.73 Surprisingly, oxalate does not appear on the list of candidate biomarkers despite
wide-spread anecdotal evidence for its involvement in autism progression,3 and a clinical
study suggesting a correlation between the elevated levels of oxalate in plasma and the
occurrence of autism.104 Oxalate is an endogenous anion, which is both produced internally
(as a final product of metabolism of glyoxalate and glycerate), and acquired with food
(especially through diets reach in leafy greens, but also from a variety of other sources
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ranging from chocolate to tofu). As there are no enzymes in humans that can degrade
oxalate, the only channel of its elimination from circulation is through the kidney, with a
typical plasma concentration in healthy adults being 10-30 µM.26 While kidney stone
formation is probably the best known pathology linked to increased levels of oxalate,
hyperoxaluria may also affect other organs and tissues, including the myocardium and bone
marrow, through systemic oxalosis.19
Anemia is also one of the well-documented clinical presentations of systemic oxalosis,
which is linked to oxalate deposition in the bones.34 Conceivably, limited availability of
iron may also be caused by oxalate interfering with iron delivery to cells (e.g., increased
levels of oxalate may lead to this anion replacing carbonate from the (Fe3+·CO32-)2·Tf
complexes in circulation; with the resulting (Fe3+·C2O42-)2Tf complexes unable to release
iron in the mildly acidic endosomal environment, see Figure 2.1). Since the insufficient
supply

of

iron

to

the

developing

brain

is

known

to

have

devastating

consequences,15,60,86,119,134,155,216 arguments have been repeatedly made that iron
deprivation may also play a role in the etiology of autism. However, multiple studies of the
iron status in autistic children failed to reach a consensus whether oxalate is a contributing
factor to iron deprivation.
However, it is important to note that even abundant plasma oxalate may not
necessarily interfere with iron delivery to the central nervous system via receptor-mediated
transcytosis, as this anion fails to displace carbonate from Tf in vitro at neutral pH on a
physiologically relevant time scale.120 The ability to determine the level of Tf complexed
with oxalate in clinical samples opens a host of exciting opportunities in this field by
providing a powerful analytical tool to establish the role of this ubiquitous metabolite in

42

modulating iron supply within the developing organism. Definitive proof of oxalate
interference with iron delivery in autistic patients would provide an explanation for the
frequent ineffectiveness of iron supplementation. Otherwise, it would bring into question
the effectiveness of the aggressively marketed low-oxalate diets, at least with respect to
ensuring sufficient iron supply, which appear to be common dietary interventions in autistic
children.3

2.5

Conclusions
Tf-bound oxalate is expected to disturb iron homeostasis by inhibiting its release

during Tf receptor-mediated endocytosis, potentially leading to a range of pathological
conditions triggered by iron deprivation. Although the plasma levels of oxalate can be
readily determined using a variety of techniques, currently there are no methods to
determine the extent of oxalate bound to Tf in circulation. We have developed an analytical
procedure that uses native ESI MS to identify synergistic anions bound to Tf in clinical
blood samples without introducing artefacts that alter the carbonate/oxalate ratio.
Therefore, this procedure may allow direct quantitation of different forms of Tf to be
carried out. Application of this new technique to the analysis of blood samples of patients
with various forms of anaemia and/or hyperoxaluria will allow the role of oxalate in
limiting iron bioavailability to be established. This information will be invaluable for the
design of a targeted and effective treatment of various pathologies triggered by iron
deprivation without relying on iron supplementation, which frequently fails. The work
presented in this report had focused specifically on the composition of Tf/metal/synergistic
anion complexes in vivo. However, a similar strategy may also be used for the analysis of
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other clinically relevant non-covalent complexes whose composition may provide
important information regarding disease diagnosis, its progression or the treatment
progress.
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2.7

Figures

Figure 2.1. Iron delivery to cells by Tf via receptor-mediated endocytosis (top) and inhibition
of this process by oxalate acting as a synergistic anion instead of carbonate (bottom). Top
(counter-clockwise, from upper left corner): binding of (Fe·CO32-/C2O42-)2Tf to TfR at the cell
surface is followed by internalization of this complex in an endosome. Activation of proton
pumps (blue) leads to the endosome acidification, a process that eventually triggers iron
release from Tf and its subsequent transport from the endosomal compartment to the cytosol,
while the iron-free Tf is recycled back to the cell surface, where it is made available for
another cycle of iron delivery. Bottom: presence of oxalate prevent iron dissociation from Tf
at mildly acidic endosomal pH.
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Figure 2.2. Zoomed views of the native ESI mass spectra of recombinant Tf reconstituted
with iron using carbonate (blue trace) and oxalate (red) as synergistic anions. The black trace
represents the ionic signal of the apo-form of recombinant Tf. Only peaks corresponding to
ionic species at charge state +20 are shown for clarity.
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Figure 2.3. SEC chromatograms of bovine serum showing the Tf-containing fraction
(highlighted in orange); native ESI mass spectrum of this fraction is shown in the inset (black
trace). Serum albumin and Tf peaks are labeled with blue and red circles, respectively. The
brown trace shows a mass spectrum of unfractionated serum.
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Figure 2.4. Zoomed views of the native ESI mass spectra of mixtures of recombinant Tf
reconstituted with iron using carbonate and oxalate as synergistic anions subjected to SEC
fractionation (top) and albumin depletion on a BDR column (bottom). The black traces
represent the spectra acquired after the treatments, and the red-filled curves represent the mass
spectra of the initial mixtures. Only peaks corresponding to ionic species at charge state +20
are shown for clarity.
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Figure 2.5. Zoomed views of the native ESI mass spectra of the apo-form of human Tf
subjected to SEC fractionation (red trace) and albumin depletion on the BDR column (blue).
The black trace represents the reference mass spectrum of the apo-Tf.
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Figure 2.6. Representative native ESI mass spectra of endogenous Tf extracted from serum
of two patients (black traces). The red-filled curves represent reference mass spectra of the
apo-forms of endogenous Tf acquired following acidification of the extracts to induce
dissociation of both iron and synergistic anions from the protein. Only peaks corresponding
to ionic species at charge state +19 are shown for clarity.
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2.9 Supplemental Figures
1N84

1RYO

carbonate

oxalate

Tyr 188

Tyr 188
Fe

His 249

Fe
His 249

Asp 63
Tyr 95

Asp 63
Tyr 95

Figure S2.1. Carbonate (left) and Oxalate (right) coordinated Fe in the N-lobe of Tf
aTf

[(Fe 3+ CO32-)2 Tf ] +20

+20

229.9

[(Fe 3+ CO32-)2 Tf ] +21

+21

230.0

aTf

Figure S2.2. Calculated mass shifts between holo- and apo-Tf for the +21 and +20 charge
states. Theoretical mass shift is for two Fe3+ and CO32- is 229.7Da.
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+Hexose

+Sialic Acid

+21

-Sialic Acid

aTf

Figure S2.3. Shown is the +21 charge state of aTf. Dashed lines represent the calculated
mass shift for either the addition of a hexose due to glycation (162.1 Da) as well as the
addition or absence of a sialic acid (291.2 Da).
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aTf

+21

MW (Experimental): 79,542 + 30Da
MW (Calculated): 79,569 Da

Figure S2.4. Calculated mass is based on the amino acid sequence of Tf and the mass of
two fully sialylated biantennary glycan chains. This figure highlights the importance of
experimentally determining the mass of aTf in order for the correct synergistic anion and
metal composition to be assigned.
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[(Fe 3+ C 2O42-)2Tf ]
[(Fe 3+ C 2O42- CO32-)Tf ]

Carbonate/Oxalate Mixure
SEC
BDR

[(Fe 3+ CO32-)2 Tf ]

Synergistic Anion
Composition
2 CO32CO32/ C2O42
2 C2O42

% Area
Orig. Mix SEC

BDR

21.5%
28.5%
50.0%

24.0%
27.9%
48.0%

23.8%
27.1%
49.1%

Figure S2.5. Deconvoluted spectra of recombinant Tf reconstituted with iron using
carbonate and oxalate as synergistic anions subjected to SEC fractionation (red) and
albumin depletion on a BDR column (blue). Peak area’s were integrated and there was no
significant change in the percent area for any of the three synergistic anion peaks.
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CHAPTER 3
INFLUENCE OF GLYCAN MODIFICATGION ON IGG1 BIOCHEMICAL AND
BIOPHYSICAL PROPERTIES
This chapter has been adapted from a paper submitted as: Pawlowski, J. W., BajardiTaccioli, A., Houde, D., Feschenko, M., Carlage, T. & Kaltashov, I. A. Influence of
glycan modification on IgG1 biochemical and biophysical properties. J. Pharm. Biomed.
Anal. 151, 133-144, doi:https://doi.org/10.1016/j.jpba.2017.12.061 (2018).

3.1

Abstract
Monoclonal antibodies (mAbs) are the fastest growing class of biopharmaceuticals.

The specific therapeutic tasks vary among different mAbs, which may include
neutralization of soluble targets, activation of cytotoxic pathways, targeted drug delivery,
and diagnostic imaging. The specific therapeutic goal defines which interactions of the
antibody with its multiple physiological partners are most critical for function, and which
ones are irrelevant or indeed detrimental. In this work, we explored the ability of the glycan
chains to affect IgG1 interaction with two key receptor families, FcRn and γ-type Fc
receptors, as well as the influence of glycan composition on the conformation and stability
of the antibody molecule. Three different glycan-modified forms of IgG1 (fully
deglycosylated, hypergalactosylated and hypersialylated) were produced and characterized
alongside the unmodified mAb molecule. Biophysical measurements did not reveal any
changes that would be indicative of alterations in the higher order structure or increased
aggregation propensity for any of the three glycoforms compared to the unmodified mAb,
although the CH2 domain was shown to have reduced thermal stability in the fully
deglycosylated form. No significant changes were observed for the hypergalactosylated
and hypersialylated forms of IgG1 with regards to binding to FcRn, FcgRIIA and FcgRIIIA,
suggesting that neither half-life in circulation nor their ability to induce an immune
response are likely to be affected by these modifications of the glycan chains. In contrast,
no measurable binding was observed for the deglycosylated form of IgG1 with either
FcgRIIA or FcgRIIIA, although this form of the antibody retained the ability to associate
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with FcRn. These highly specific patterns of attenuation of Fc receptor recognition can be
exploited in the future for therapeutic purposes.
3.2

Introduction
Monoclonal antibodies (mAbs) are a large and fast growing class of

biopharmaceuticals used to treat a wide range of diseases. Of the five classes of antibodies,
the majority of all currently licensed therapeutic mAbs use immuglobulin gamma (IgG) as
their framework

1,2

. IgG consists of a fragment antigen binding (Fab) domain and a

fragment crystalline (Fc) domain. The latter is responsible for Fc gamma receptor (FcgR)
and neonatal Fc receptor (FcRn) binding. There are four major subtypes of IgG (IgG1,
IgG2, IgG3, and IgG4), each having different properties with respect to antigen target,
complement activation, and affinity for FcgRs 3.
The most important IgG effector functions are achieved through binding to FcgRs
on the surface of leukocytes leading to the activation of the immune system.4 There is one
inhibiting (FcgRIIb) and four activating (FcgRI, FcgRIIa, FcgRIIIa, FcgRIIIb) receptors
present in humans

5,6

. IgG effector functions that are mediated through the binding of

FcgRs-presenting cells include antibody-dependent cellular cytotoxicity, antibodydependent phagocytosis, degranulation, cytokine release, and inhibition of cell activities
among other functions.3,4 Neonatal Fc receptor (FcRn) is a unique type of Fc receptor
responsible for IgG longevity in circulation (half-life of up to three weeks) 7. Circulating
IgG molecules are taken up by cells through pinocytosis and directed to endosomal
compartments. Upon endosome acidification (pH < 6.5) FcRn binds to the CH2/CH3 region
of IgG and rescues it from being routed to and degraded in the lysosome. FcRn-bound IgG
is then returned to the cell surface and released at physiological pH (7.4) back into
circulation. This pH dependent binding is thought to be due to several pH-titratable
residues at the FcRn-Fc binding interface 8. FcRn is also able to transport IgG molecules
across epithelial barriers

9

including the placenta (and thus playing a critical role in

establishing and maintaining immunity by transferring antibodies from mother to child) 10.
Interactions of the antibody with its targets and receptors must be considered when
developing a new therapeutic mAb, as they ultimately determine all aspects of its activity
and pharmacokinetic (PK) properties, e.g., target recognition (Fab/antigen binding),
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activation of the immune response (Fc/FcgR binding) and half-life (Fc/FcRn association
and interaction with neutralizing antibodies 11). However, the relative importance of each
individual type of interaction depends upon the specific task the new biotherapeutic is
designed to accomplish (e.g., soluble target neutralization, cell destruction, drug delivery,
imaging, etc.). For example, in drug delivery or imaging applications the emphasis is
placed on the Fab/antigen interaction (in fact, an immune response to the target of interest
is likely to be an unwanted side effect in this case, and the mAb effector function should
be diminished or eliminated). In contrast, effective targeting of cancer cells would depend
upon a strong immune response, placing emphasis on optimizing Fc/FcgR interactions.
Glycosylation is a structural feature common to many therapeutic proteins, including
most mAbs used in clinical applications. In mAbs, glycan chains can have a significant
impact on both PK properties and the effector function. The single (and highly conserved)
glycosylation site is located at position N297 in the CH2 domains of each heavy chain
(Figure 3.1), and each glycan chain interacts with the CH2 domain and the opposite glycan
chain

3,12

. While the localization of the glycan chains within the Fc region makes their

influence on antigen binding highly unlikely, their unique “introverted” arrangement plays
an important role in forming and maintaining the conformation of Fc; it is therefore not
surprising that changes in the glycan composition alter many aspects of functionality,
stability and PK profile of mAbs 13. It has been reported that sialylation of IgG molecules
enhances their anti-inflammatory properties through a decreased affinity to FcgRIIIa 12 and
a proposed interactions with dendritic cell-specific intercellular adhesion molecule-3grabbing non-integrin

3,14-16

. Furthermore, afucosylated, terminal galactose, and high

mannose glycan species have all been reported to affect the PK profile and effector function
of IgG

17,18

. It is very important to understand how glycosylation may affect the effector

function and PK profile of mAb for efficacy and safety reasons. It may also enable rational
design of engineered glycoforms with receptor-binding properties optimized for a specific
therapeutic function.
In this work, two glycotransferases were used to add a terminal galactose or sialic
acid to the glycan chain of an antibody (IgG1 subclass), while the glycosidase PNGase F
was used to completely remove the glycan chain. The glycan-modified mAbs were then
extensively characterized with regards to changes in stability and function (with an
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emphasis on binding to FcgRs and FcRn). Since certain steps during enzymatic
modification of mAbs may introduce non-enzymatic post-translational modifications
(PTMs) in addition to the desired enzymatic PTMs, the levels of oxidation and deamidation
were carefully controlled in the final products and compared to those in the starting
material. Furthermore, changes in the glycan composition can influence both structure and
functional properties of mAbs via two distinct routes, (i) packing and steric effects and (ii)
electrostatic effects, which were evaluated separately in this work.

The glycan

modifications were optimized to minimize other structural changes to the mAb, and these
modifications did not appear to have a significant effect on the mAbs biophysical and/or
biochemical properties. Addition of galactose and/or sialic acid did not significantly
interfere with the mAb’s binding to FcRn or FcgRIIA/IIIA. Deglycosylation of the mAb
produced a modest decrease of its affinity for FcRn, and completely abrogated binding to
FcgRIIA/IIIA, as previously reported

19,20

. Modification of a mAb’s glycan composition

opens exciting new possibilities to fine-tune its properties with the purpose of achieving a
desired therapeutic outcome

21-23

. The results of this study help to further understand the

impact of Fc glycosylation on the function and structure of an IgG1 molecule.
3.3

Results
Three glycoprotein variants (deglycosylated IgG1, hypergalactosylated IgG1 and

hypersialylated IgG1) were produced from the same mAb sample as described in the
Experimental section. All three glycan-modified mAb samples, as well as the reaction
control (IgG1 incubated in the same buffer and temperature as the glycan-modified
samples) and unmodified IgG1 were characterized as described below.
Intact Mass Spectrometry Analysis. Successful enzymatic modification of the IgG1
glycans was verified by comparing the mass spectra of the modified (enzymatically treated)
IgG1 to control (unmodified) IgG1 species (Figure 3.2). The unmodified mAb has four
major glycan chain variants, which range from having no terminal galactoses (G0/G0 in
Figure 3.2) to 3 terminal galactose residues (G1/G2). A list of all possible glycan species
is shown in the Supplementary Material (Figure S3.1). Based on the mass shift from the
G0/G0 peak of the unmodified IgG1, hypergalactosylation was shown to convert the
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heterogeneous ensemble of unmodified IgG1 molecules to a fully galactosylated species
(G2/G2 in Figure 3.2). Hypersialylated IgG1 exhibited a combination of 2, 3, and 4
terminal sialic acid residues, with the glycoforms bearing 2 and 3 sialic acid residues being
the major species (G2S1/G2S1+G2S0/G2S2 and G2S1/G2S2 in Figure 3.2). The mass of
the deglycosylated IgG1 species is consistent with a complete removal of both glycan
chains from the protein. No significant increase in either oxidation or glycation was
observed in the enzymatically modified IgG1 samples (Table 3.1, Figure S3.2 in
Supplementary Material).
Size Exclusion Chromatography. Size exclusion chromatography (SEC) was used to
evaluate the extent of aggregation of enzymatically treated IgG1 samples by monitoring
formation of both soluble aggregates. None of the enzymatic modifications used in this
work resulted in a detectable shift of the retention time for the main (monomer) peak. The
level of the soluble aggregate formation was found to be less than 2% (by absorbance) for
all IgG1 samples, including fully deglycosylated one (Table S1), suggesting that no the
experimental conditions to modify the glycan did not significantly alter molecular stability
or lead to increased levels of protein aggregates.
Lys-C peptide mapping. Lys-C peptide mapping of all IgG1 samples was carried out
using reversed phase liquid chromatography with detection by mass spectrometry
(LC/MS). The generated peptide maps were used to detect and quantitate several possible
PTMs that could be present in the intact IgG1 sample and generated as side products of the
glyco-modification treatment (e.g., oxidation, deamidation, and glycosylation). Possible
oxidation of the protein was a particular concern, as the FcRn binding interface
incorporates two conserved 24 methionine residues present on each HC (Met252 and Met428,
located in peptides L17 and L32, respectively). Oxidation of either methionine has been
shown to negatively affect the binding of IgG1 to FcRn, provided its twin methionine
residue (located on another HC chain) is also oxidized

24-26

. Deamidation introduces a

negative charge into a protein and in some cases, is accompanied by isomerization which
elongates the polypeptide backbone. Somewhat elevated levels of deamidation were
observed in peptide L19-20 containing Asn304 and Asn322, and of which are located close
to the FcRn binding interface (see Figure 3.1) and are known to be prone to deamidation
27,28

. Glycosylated peptides were monitored to confirm the glycan composition of the
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hypergalactosylated and hypersialylated IgG1 samples; in the case of the deglycosylated
IgG1, successful removal of the glycan chain was verified by the absence of any
glycopeptides in the Lys-C digest (Table 3.2).
An example of non-enzymatic PTM quantitation (oxidation of Met252) using LC/MS is
illustrated in Figure 3.3, and Table 3.1 compares the relative levels of oxidation and
deamidation in both modified and unmodified IgG1 molecules. Peptide maps for the
hypergalactosylated and hypersialyated IgG1 species show a modest increase of oxidation
of Met252 and Met428. Importantly, the estimated percentage of modified IgG1 molecules
with oxidation at both methionine residues is less than 2% for all samples; therefore,
oxidation is not expected to impact FcRn binding. There is a slight increase of deamidation
for both hypergalactosylated and hypersialyated IgG1 (Table 3.1), although this has not
been reported to affect FcRn binding (vide supra). Deglycosylated IgG1 showed a decrease
in oxidation of the two methionine residues, and a modest increase of deamidation. The
decrease in oxidation is due variability in sample handling of the deglycosylated IgG1 from
the other samples were prepared from aliquots held at 2-8 Co for > 2 weeks. The reaction
control IgG1 sample showed a minor increase in oxidation and deamidation levels
following exposure to the reaction conditions for hypersialylated IgG1 sans
sialyltransferase as, but the absence of major changes indicates reaction conditions do not
adversely affect IgG1.
Relative abundance of observed glycopeptides for each IgG1 sample was calculated
(Table 3.2). For hypergalactosylated IgG1, the only identified glycopeptide was found to
have a G2 glycan chain (core complex glycan moiety with two terminal galactoses). This
is consistent with the intact mass measurement which showed IgG1 being fully
galactosylated (see Figure 3.2). Hypersialylated IgG1 contained a mixture of
glycopeptides with one or two terminal sialic acid glycans (G2S1 and G2S2, one and two
terminal sialic acids respectively), consistent with the intact mass measurement which
showed only IgG1 glycans with 2, 3, and 4 terminal sialic acids (see Figure 3.2). No
glycopeptides were detected in the deglycosylated IgG1 sample, as was expected since the
intact mass measurement shows no glycans attached to IgG1 (see Figure 3.2).
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Second Order Derivative UV-VIS Spectroscopy. Second order derivative UV-VIS
spectroscopy was performed to monitor changes in absorbance of aromatic residues in the
modified IgG1 samples. Plots of second order derivatives of the absorption spectra for all
IgG1 samples are shown in Figure 3.4. No significant change is observed, consistent with
the absence of global structural change for any of the IgG1 samples.
Differential Scanning Calorimetry. Differential scanning calorimetry was used to
assess the thermal stability of the IgG1 samples. Thermograms of the IgG1 samples
examined in this work (Figure 3.5) show multiple transitions, the lower of which is
assigned as thermal unfolding of the CH2 domain (Tm1), while the higher-temperature
transitions (Tm2/3) are assigned as thermal unfolding of the Fab and CH3 domains.29,30 No
temperature change of either thermal transition was observed for the hypergalactosylated
IgG1 as compared to unmodified IgG1, while deglycosylated IgG1 had noticeably lower
Tm1, consistent with a previous study.31 Interestingly, hypersialylated IgG1 had slightly
lower temperatures for both transitions, with the downward shift of the higher-temperature
transition being more pronounced. Regardless of the reason for the modest decrease of
Tm2 in the hypersialylated IgG1, it is not expected to have significant impact on its longterm stability.30
Biolayer Interferometry Binding Kinetics. A biolayer interferometry assay was used to
measure the kinetics of IgG1 association to and dissociation from the FcRn fusion protein.
The experimental curves (Figure 3.6) were fitted using a 1:1 binding model to generate
association and dissociation rate constants (kon and koff), as well as the dissociation constant
(KD, calculated as koff/kon)
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. The calculated KD values are presented in Table 3.3. The

reaction control IgG1 sample did not show a change in its KD value as compared to the
unmodified IgG1. Deglycosylated IgG1 was found to have a modest increase in KD, while
both hypergalactosylated and hypersialylated IgG1 samples showed a modest decrease in
KD values.
Fcg Receptor Binding. AlphaScreen-based competitive FcRn, FcgRIIa, and FcgRIIIa
assays were used to measure the relative potency for each modified form of the IgG1
(compared to the unmodified IgG1). The results are shown in Figure 3.7 and Figure 3.8.
Deglycosylated and hypergalactosylated IgG1s were observed to have a decrease of their
relative potency for FcRn. Conversely, the reaction control and hypersialylated IgG1s were
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observed to have an increase of their relative potency for FcRn. Deglycosylated IgG1 was
not observed to bind either FcgRIIa or FcgRIIIa. Hypergalactosylated and hypersialylated
IgG1 showed a minor decrease and increase of its relative potency for FcgRIIa and
FcgRIIIa, respectively.
3.4

Discussion
The goal of this study was to understand how specific changes to this IgG1 glycan

chain affect both biophysical properties of the protein and its ability to bind to Fc receptors.
To that end, fully deglycosylated, hypergalactosylated, and hypersialylated IgG1
molecules were prepared enzymatically, and their structural and receptor-binding
characteristics were assessed using a variety of biophysical tools and compared to those of
intact (unmodified) IgG1. Successful modification of the glycan chains was verified by
measuring the mass of intact IgG1 molecules with ESI MS

33,34

(Figure 3.1), as well as

profiling glycopeptides in the Lys-C map of each glycoform of IgG1, including the
unmodified molecule. In addition to modifying the glycan chains, the enzymatic treatment
of the IgG1 sample may inadvertently introduce unintended non-enzymatic PTMs (such as
oxidation, deamidation and glycation). Among the several non-enzymatic PTMs that
frequently affect monoclonal antibodies during both production and storage, oxidation is
particularly critical in the context of this study. First, extensive oxidation is known to have
a negative impact on the conformational integrity of proteins
both methionine residues at the FcRn binding interface (Met
detrimental to FcRn binding

24-26

252

35-37

. Second, oxidation of

and Met428) is known to be

. Should the extensive oxidation occur during the

enzymatic treatment of IgG1, the resulting instability of the protein and/or its inability to
interact with FcRn might be incorrectly correlated with a particular structural feature of the
glycan chain. Both the occurrence and the extent of non-enzymatic PTMs were determined
by careful examination of the Lys-C peptide maps for each of the glycoforms. No
significant increase in non-enzymatic PTMs (deamidation or oxidation) were observed that
would be detrimental to the stability of IgG1 or its ability to bind FcRn. Indeed, it would
require the oxidation level for Met252 and Met428 to exceed 50% (a recent study failed to
observe a significant difference in serum clearance profiles between the intact IgG1 and its
modified version in which the oxidation level of one of the key Met residues was 50% 25).
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The absence of extensive non-enzymatic PTMs triggered by glycan chain modification
procedures in IgG1 samples is important, as it allows all observed changes in the stability
of the higher order structure, as well as receptor-binding characteristics of the modified
protein samples to be attributed directly to the change in the glycan structure. The only
exception is the deamidation observed in the fully deglycosylated IgG1, where elevated
deamidation levels were observed (Table 3.1). The affected residue (Asn322) are located
near the FcRn binding interface of the antibody (see Figure 3.1) and are highly unlikely to
have any influence on its association with either of the Fcγ receptors examined in this work;
there are no reports of deamidation in this region of the IgG1 Fc having any impact on
FcRn binding.
Second-order derivative UV-VIS does not provide any indication of a tertiary structure
change for any of the modified IgG1s (Figure 3.4). Second order derivative UV-VIS
spectroscopy is a sensitive probe of the environment of aromatic side chains in protein
molecules.38,39 These residues are present in all domains of the molecule (see the inset in
Figure 3.4, where positions of Tyr, Phe and Trp residues are shown within the IgG1
structure), lending them a useful probe of the changes in conformational integrity.40
Therefore, absence of any changes in the second order derivative UV-VIS absorption
spectra provides a strong indication that there are no significant (large-scale)
conformational changes. Consistent with this conclusion, changes in the glycan
composition (including complete deglycosylation) did not result in a detectable change in
the elution time of the IgG1 monomer peak in SEC chromatograms (Table S1 in
Supplementary Material), suggesting the consistency of the hydrodynamic radius across
the different variants studied. Furthermore, the extent of dimerization (based on the relative
abundance of the dimer peak in the SEC chromatograms) is also unaffected by the
composition of the glycan chain. This provides a strong indication that the aggregation
propensity of the IgG1 molecules (which is commonly thought of as being linked to the
changes in the higher order structure) 41-43 is not altered by either modification or removal
of the glycans. Deglycosylation can have a profound negative effect on the solubility of
many proteins 44,45 (a loss of even a single glycan chain may lead to significant aggregation
46

); furthermore, removal of the glycan chains has been shown to have a detrimental effect

on the stability of the CH2 domain of an antibody under acidic conditions 47. However, we
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have not observed any loss of solubility for the antibody molecule after deglycosylation at
physiologically relevant pH; this should not be surprising, given the unusual “inward”
orientation of the glycan chains within the native conformation of the homo-dimeric IgG1
molecule, where it can hardly act as a solubility enhancer.
While the higher order structure of the IgG1 molecules does not appear to be
compromised as a result of its complete deglycosylation, the conformational stability does
change upon removal of the glycan chains. DSC measurements clearly demonstrate a
significant (> 5OC) decrease of Tm1 in the deglycosylated IgG1 sample compared to the
unmodified molecule (Figure 3.5). This transition is usually interpreted as thermal
unfolding of the CH2 domain,30 and the dramatic decrease in the melting temperature of
this domain upon the complete removal of glycans suggests that the inward orientation of
the glycans within the homo-dimer enhances its stability by providing additional
interactions between the two units forming the homo-dimeric structure. While it might be
tempting to speculate that the increased level of deamidation in the CH2 domain observed
in the deglycosylated IgG1 sample may also contribute to decreased thermal stability, a
significant fraction of the IgG1 molecules in this sample are not affected by deamidation.
Should this PTM result in loss of thermal stability, a split peak would be observed in the
thermogram representing both deamidated (Asp322) and intact (Asn322) populations; in
contrast to this, a single well-defined peak is observed in the Tm1 region of the
thermogram, indicating that the entire ensemble of the deglycosylated IgG1 molecules
suffers from the decrease of thermal stability. Above and beyond the CH2 domain,
deglycosylation does not appear to affect the thermal stability of the IgG1 molecule (no
shift in Tm2/3 is evident in Figure 3.5), consistent with the notion that the stabilizing
effects of the glycan chains are localized within the CH2 domain and to not affect thermal
stability of either CH3 or Fab regions of the molecule.
Hypergalactosylation does not result in any detectable changes in either Tm1 or Tm2/3,
which is hardly surprising given the relatively modest increase of the length of the glycan
chain (compared to the unmodified IgG1). On the other hand, hypersialylation of IgG1
does give rise to modest, but detectable shifts of both Tm1 and Tm2/3 (Figure 3.5). The
slight (ca. 1.5 OC) decrease in Tm1 is not surprising, as the introduction of two to four
negative charges within the relatively small interstitial space between the two CH2
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domains is likely to exert at least some destabilizing effect due to Coulombic repulsion.
Intriguingly, the effect of the electrostatic repulsion is also felt outside of the CH2 domains,
as indicated by a modest decrease of Tm2/3 (ca. 2 OC) compared to all other IgG1 samples.
This modest decrease of Tm2/3 is suspected to be destabilization of the CH3 domain due
to the proximity of the glycan chain.
Even though the DSC measurements clearly demonstrate a modest decrease of thermal
stability of IgG1 following hypersialylation, these changes are too small to have a
measurable negative impact on the protein stability at either room or body temperature.
Furthermore, even though the CH2 domain appears to be sensitive to the effects of
hypersialylation, neither FcRn nor FcγRIIA/FcγRIIIA binding is affected by
hypersialylation (for which the binding interfaces are located in the CH2/CH3 and the
CH2/lower hinge regions, respectively 23), as demonstrated by the results of the biolayer
interferometry and the AlphaScreen measurements. FcRn is responsible for the long halflife of IgG1 molecules in circulation (by rescuing them from lysosomal degradation in
macrophages 8, which is the major clearance route for large proteins in circulation), while
the FcRγ receptors are responsible for activation of the immune system. Highly sialylated
IgG1 molecules have been shown to possess anti-inflammatory properties

48-50

. The

absence of any measurable influence of sialylation on IgG1, interaction with either FcRn
or γ-type Fc receptors demonstrated in this work, suggests that hypersialylation can be
exploited for therapeutic purposes without a significant impact on PK characteristics of
antibodies, at least with respect to the receptors explored in this work.
All biophysical characteristics of hypergalactosylated IgG1 assessed in this work
remain unchanged compared to the intact (unmodified) antibody, and its ability to interact
with FcγRIIA and FcγRIIIA is also preserved. This also has important practical
implications, as the increase in the content of terminal galactose residues of antibodies’
glycan chains is known to be correlated with greater complement dependent cytotoxicity
as a result of greater affinity for C1q 51. The results of our work suggest that this trait may
be exploited for therapeutic purposes without compromising PK and PD profiles of the
antibody.
Biolayer interferometry and AlphaScreen assays for FcRn displayed similar trends with
relative potency and affinity (Figure 3.7 and Table 3.3) for all modified samples excluding
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hypergalactosylated IgG1mAb. Hypergalactosylated showed contradictory results with a
lower relative potency (AlphaScreen) and higher affinity (biolayer interferometry) as
compared to the unmodified IgG1 but the minor changes observed are likely within the
range of assay variability and are not significant. Deglycosylated IgG1 was observed to
have the largest change in both assays but it has been previously reported that
deglycosylated IgG1s do not have a different in vivo half-life

52-54

. None of the observed

changes in relative potency and KD values are expected to manifest in a detectable change
in the half-lives for any of the modified mAbs.
The AlphaScreen assays for FcγRIIA and FcγRIIIA showed changes in the relative
potency for hypergalatocylated and hypersialylated IgG1 (see Figure 3.8). These changes,
however, are relatively minor compared to those that are known to elicit observable
changes in the in vivo behavior of IgG1. For example, afucosylated IgG1 is reported to
have a fifty-fold affinity increase towards FcγRIIIA, and exhibited a higher antibody
dependent cellular cytotoxicity

21

. The magnitude of the changes observed for both

hypergalactosylated and hypersialylated forms of the IgG1 is not significant enough to
result in measureable changes in vivo. Additionaly, deglycosylated IgG1 was not observed
to bind either FcγRIIA or FcγRIIIA. Consistent with earlier reports 19,20, this inability for
deglycosylated IgG1 to interact with either FcgRIIA or FcgRIIIA is expected to eliminate
its ability to activate immune cells expressing these receptors.
Perhaps the most important observation related to IgG1 glycoforms’ interactions with
Fc receptors is a complete loss of the ability of the deglycosylated IgG1 to interact with
FcgRIIA and FcgRIIIA receptors, while maintaining FcRn affinity A modest decrease in
FcRn affinity for deglycosylated mAbs had been reported previously 55 and the complete
obliteration of their ability to associate with FcgRIIA or FcgRIIIA is also consistent with
the previously published work 12. However, it seems puzzling that the complete removal
of the glycan chains from the IgG1 molecule (a process which is shown in our work to have
a negative influence on conformational stability of the CH2 domain) exerts such vastly
different effects on its interactions with two Fc receptors (modest decrease of FcRn binding
and completely obliterating γ-receptor binding), even though each relies on CH2’s
structure to provide a part of a binding interface (see Figure 3.1). A more detailed study
would be needed to understand the differential effect of the glycan chains on the
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stability/integrity of different parts of the CH2 domain that are involved in the interactions
with these two different types of Fc receptors. Regardless of the specific mechanisms
involved in attenuating the receptor-binding properties, this behavior of glycan-free
antibodies makes them highly attractive as vehicles in targeted drug delivery applications,
where both the long half-life and the absence of immune response are needed. The former
would be guaranteed by conformational integrity of the molecule at both room and body
temperature, as well as enhanced interactions with a “rescue” receptor (FcRn), while the
latter (an abrogated effector function) is ensured by the lost ability to interact with the γtype Fc receptors, thereby avoiding an undesirable immune response. While disrupting a
mAb’s interaction with FcgR’s can be readily achieved by mutating key residues in the
binding interface located in the CH2/lower hinge region, an unintended consequence of
this could be an immune response to the neo-epitope not present in the wild-type molecule;
elimination of the glycan chain might provide an alternative approach to this problem that
would not trigger productions of the neutralizing antibodies by the host.
The study of the impact of glycosylation attributes on specific IgG functions can be
leveraged for risk assessments of therapeutic mAbs. The risk assessment performed on
product quality attributes of biopharmaceuticals (see ICH Q8(R2) and Q11) requires
assessment of the potential impact of different attributes on a drug’s efficacy,
pharmacokinetic properties, and safety

56,57

. These risk assessments can help inform

process development, and enable an analytical control strategy that can be used to ensure
proper control of critical quality attributes (CQAs) within the process. Often, structureactivity relationship studies are performed to provide relevant data to help inform these
risk assessments to understand which product attributes are most critical. Previous studies
have shown the criticality of specific glycan species such as afucosylated glycans and high
mannose glycans on effector function via the FcγRIIIa pathway

17,18

. This study queried

the potential impact of elevated levels of terminal galactose or terminal sialic acid on Fc
receptor interactions. In both cases, no significant impact was observed. The data shown
here provides important context when assessing the criticality of IgG1 glycosylation, in
terms of any potential impact on PK and effector function.
3.5

Conclusions
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Three different glycan-modified forms of mAb (deglycosylated, hypergalactosylated
and hypersialylated) were produced and characterized alongside the intact mAb molecule.
Biophysical measurements have not revealed any changes that would be indicative of
alterations in the higher order structure of the mAb or increased aggregation propensity for
any of the three forms compared to the intact mAb, although reduced thermal stability in
the CH2 domain was observed for the fully deglycosylated form by DSC. The
deglycosylated mAb showed a modest decrease in FcRn affinity (though not expected to
affect its half-life) while having no binding to FcgRIIa and FcgRIIIa. Depending on the
mechanism of action required for a mAb, an aglycosylated or deglycosylated mAb may be
attractive for use if effector functions are undesirable while retaining a long half-life. No
significant changes were noted for binding of the hypergalactosylated and hypersialylated
forms of IgG1 to both FcRn, FcgRIIA, and FcgRIIIA suggesting that neither the half-life
in circulation nor the ability to induce an immune response are affected by these
modifications of the glycan chains. The results described provide valuable information
regarding the criticality of IgG1 galactosylation and sialylation that can be leveraged
during risk assessments and process characterization studies. These attributes may also be
of interest to researchers using a therapeutic mAb with a high percentage of terminal
galactose and or sialylated glycan chains.
3.6

Experimental
IgG1 Deglycosylation. IgG1 was buffer exchanged into a 100 mM tris-acetate buffer

(pH 7.5). 20 mg of IgG1 was added to a 1.5 mL vial with 10 µL of PNGase F (500,000
U/mL, New England Biolabs, Ipswich, MA) and diluted up to 600 µL with 100 mM trisacetate buffer (pH 7.5). The sample was incubated in a water bath at 37 oC for 24 hours.
After incubation, deglycosylated IgG1 was buffer exchanged into a 50 mM MOPS buffer
(pH 7.2) and stored at -80 oC.
IgG1 Hypergalactosylation. IgG1 was buffer exchanged into a 100 mM tris-acetate
buffer (pH 7.5). 20 mg of IgG1 was added to a 2 mL vial with 10 µL of MnCl2 (10 mM),
200 µL UDP-Galactose (EMD Millipore Corp., Billerica, MA) (25mg/mL), and 250 µL
galactosyltransferase (Sigma-Aldrich Co., St. Louis, MO) (2 U/mL). The volume of the
solution was adjusted to 1000 µL with 100 mM tris-acetate buffer (pH 7.5) and incubated
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in a water bath at 37 oC for 24 hours. After 24 hours, 10 µL of a 10 mM solution of MnCl2
(Fisher Scientific, Hampton, NH), 5 mg UDP-Galactose (25 mg/mL), and 0.5 units of
galactosyltransferase (2 U/mL) were added to vial and incubated in a water bath at 37 oC
for an additional 24 hours. After incubation, hypergalactosylated IgG1 was purified by size
exclusion chromatography to remove excess reagents. Hypergalactosylated IgG1 was
buffer exchanged into a 50 mM MOPS buffer (pH 7.2) and stored at -80 oC.
IgG1 Hypersialylation. IgG1 was first hypergalactosylated as described above, since
the sialyltransferase used will only add sialic acid to glycan chain with a terminal galactose.
Two hypersialylation reactions were run in parallel as follows: 12.5 mg of
hypergalactosylated IgG1, 30 mg of CMP-Sialic Acid, and 0.5 mg sialyltransferase (Roche
Life Science, Penzberg,Germany)(5.7 mg/mL) were added to a 2 mL vial. The volume of
the solution was adjusted to 1500 µL with 100 mM tris-acetate buffer (pH 7.5) giving the
final concentration of the enzyme 0.33 mg/mL. and incubated in a water bath at 37 oC for
8 hours. After incubation, hypersialylated IgG1 was purified by size exclusion
chromatography to remove excess reagents. Hypersialylated IgG1 was buffer exchanged
into a 50 mM MOPS buffer (pH 7.2) and stored at -80 oC.
Size Exclusion Chromatography. Size exclusion chromatography (SEC) measurements
were carried out using an Agilent 1100 HPLC system (Agilent Technologies, Santa Clara,
CA). IgG1 samples (100 µg total protein mass) were individually injected onto an SEC
column (Tosoh TSKgel G3000SWxl, Tosoh, Tokyo, Japan) using a 150 mM ammonium
acetate buffer (pH 6.8) with at a 1 mL/min flow rate. Absorbance was monitored at 280
nm and peaks were integrated manually using ChemStation software (Agilent
Technologies).
Mass Spectrometry. Electrospray ionization mass spectrometry (ESI MS) was used to
monitor modification or complete removal of the IgG1 glycan chain by measuring intact
protein mass. IgG1 samples (50 µg) were injected onto a MassPREP online desalting
(Waters, Milford, MA) column and using a two mobile phase gradient (A: H2O, 0.1% (v/v)
formic acid B: 10:90 (v/v) H2O/ acetonitrile, 0.1% (v/v) formic acid). The eluting protein
fraction was collected for ESI MS analysis. A SolariX 7 (Bruker Daltonics, Billerica, MA)
Fourier transform ion cyclotron resonance mass spectrometer (FT ICR MS) with a 7.0 T
superconducting magnet was used to acquire MS data of desalted IgG1 samples.
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Lys-C Peptide Mapping. IgG1 samples were digested with a Lys-C protease (Wako
Pure Chemical Industries, Richmond, VA) and reversed phase (Agilent Zorbax 300-SDC18) liquid chromatography (HP 1100, Agilent Technologies, Santa Clara, CA) coupled
with a SolariX 7 FT ICR MS was used to generate peptide maps. Solution aliquots
containing 5 µg of peptides (total peptide mass) were injected onto the C18 column and
eluted using a two mobile phase gradient (A: H2O, 0.1% (v/v) formic acid B: 10:90 (v/v)
H2O/acetonitrile, 0.1% (v/v) formic acid). Each peptide map was used to detect occurrence
and evaluate the extent of two specific non-enzymatic PTMs (oxidation and deamidation).
The presence of glycopeptides was also monitored to confirm the addition of sugars to the
glycan chain. Peak areas for various PTMs were integrated manually using built-in data
analysis software to calculate their relative abundance.
Second Order Derivative UV-VIS Spectroscopy. Normalized second order derivative
UV-VIS absorbance spectra of the protein samples were calculated based on the
absorbance measurements carried out over a wavelength range of 200 nm to 600 nm using
Agilent Technologies (Santa Clara, CA) 8453 spectrophotometer.
Differential Scanning Calorimetry (DSC). DSC thermograms were obtained with a
MicroCal VP DSC (Malvern, Westborough, MA) in the temperature range from 25 oC to
100 oC at a 200 oC/hour scan rate and analyzed using Origin 9.0 (Origin Lab, Northampton,
MA).
FcRn binding assessment by Biolayer Interferometry. FcRn-Fc fusion protein: FcRnhuM4Fc, a soluble dimeric Fc binding protein was constructed by genetically fusing the
extracellular domain of a neonatal receptor with the Fc region of an IgG1 antibody, as
described in US 8,618,252 B258 (Farrington et al., Biogen Idec, Cambridge, MA) to use as
reagent in the binding assays. FcRn-huM4Fc is a FcRn-Fc fusion protein, consisting of two
beta-2-microglobulin and two FcRn alpha-Fc fusion chains, where the Fc region was
mutated by site-directed mutagenesis from the wild type sequence at residues 388, 389,
511, and 512 to eliminate the likelihood of the FcRn-huM4Fc binding to itself.
Biotin-FcRn-Fc: FcRn-huM4Fc was biotinylated using ChromaLink Biotin
(catalog # B-1001-1005, Solulink, San Diego, CA) at a biotin/protein molar ratio of 3/1
following manufacturer’s procedure.
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Biolayer Interferometry: A fortéBio Octet® QKe system and streptavidin (SA) biosensors (cat# 18-0009) were purchased from Pall ForteBio Corp. (Menlo Park, CA). This
instrument was used to study kinetics of IgG1 protein samples binding to FcRn. The assays
were performed in solid black 96-well plates (Greiner Greiner Bio-One, cat #65520), using
streptavidin biosensors (SA), with agitation set at1000 rpm, and temperature set at 30°C.
All reagents were diluted in assay diluent containing MES Buffer, pH 5.8, supplemented
with 150mM NaCl, 1.0% BSA Bovine Serum Albumin (BSA), and 0.02% Polysorbate-20.
Biotin- FcRn at 5µg/ml was used in a loading step for 300 seconds to bind FcRn to the SAbiosensor surface. A 60 seconds biosensor washing step was applied prior to the association
of the IgG1 protein samples to FcRn on the biosensor. All samples were tested at the same
concentrations, 33.3 nM, 16.7 nM, and 8.33 nM, 4.17nM, with an association step of 150
seconds, and a dissociation step of 100 seconds. Experimental data was fit with the 1:1
binding model and was analyzed with global fitting using Octet software (v. 7.1) to
calculate kon and koff rates.
FcRn binding assessment by by AlphaScreen®screen. A competition assay was used
to measure the relative potency for each modified mAb for FcRn binding. Biotin-FcRn-Fc:
FcRn-huM4Fc was biotinylated using ChromaLink Biotin (catalog # B-1001-1005,
Solulink, San Diego, CA) at a biotin/protein molar ratio of 20/1 following manufacturer’s
procedure. AlphaScreen® beads (streptavidin-coated donor beads and Human IgG1conjugated acceptor beads) were purchased from Perkin Elmer, Waltham, MA. MES (Nmorpholine ethanesulfonic acid) buffer, pH 5.8, supplemented with 150mM NaCl, and
0.1% Bovine Serum Albumin (BSA) was used as a binding assay diluent.
AlphaScreen®-based FcRn competitive binding assay was performed as described in
elsewhere

32

, using the following reagents: biotin–FcRn (0.6 µg/mL), hIgG1-conjugated

acceptor beads (10µg/mL), and streptavidin-coated donor beads (20µg/mL), final
concentrations. This assay is based on the competition between the Fc-fusion protein and
hIgG1-conjugated to acceptor beads for binding to biotin-FcRn. Biotin–FcRn and the Fcfusion protein samples were incubated for 30 minutes, followed by the addition of hIgG1acceptor beads and 30 minutes incubation, and a final step with addition of streptavidindonor beads and incubation for 60 minutes. All incubations were done in the dark with
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shaking at 22° C. All reagents were diluted in assay diluent containing. Plates were read
on EnVision Multilabel 2101, (Perkin Elmer, Waltham, MA). Each sample was tested in
triplicates. Parallel Line Analysis software (Stegmann Systems, Germany) was used to
assess the linearity, parallelism, and potency of the sample in relation to the standard.
FcgRIIa and FcgRIIIa binding assessment by AlphaScreen®screen. A competition
assay was used to measure the relative potency for each modified mAb for FcgRIIa and
FcgRIIIa binding.
FcgRIIa and FcgRIIIa reagents: Glutathione-S-Transferase (GST)-FcgRIIa and
GST-FcgRIIIa were constructed at Biogen (Cambridge, MA).
AlphaScreen® beads: Reduced Glutathione (GSH)-coated donor beads (Catalog #
6765302), and human IgG1-conjugated acceptor beads (custom made) were purchased
from Perkin Elmer, Waltham, MA.
FcgRIIa Binding assay diluent: 50 mM Tris Buffer, pH 7.2, supplemented with 25
mM NaCl, 0.1% Bovine Serum Albumin (BSA), and 0.01% Tween-20.
FcgRIIIa Assay Diluent: PBS, pH 7.2, supplemented with 0.1% Bovine Serum
Albumin (BSA), 0.01% Tween-20
AlphaScreen®-based FcgRIIa and FcgRIIIa binding assays: The assays are based
on the competition between the IgG1 protein and hIgG1- conjugated to acceptor beads for
binding to GST-FcgRIIa or GST-FcgRIIIa. The FcgRIIa and FcgRIIIa binding assays, were
carried out in white ½ area 96-well plates (catalog #3693, Corning, Tewksbury, MA), using
the following reagents: GST-FcgRIIa (6µg/mL) and GST-FcgRIIIa (10µg/mL), hIgG1conjugated acceptor beads (2µg/mL), and GSH-coated donor beads (2µg/mL), final
concentrations. The assays were performed as follows, IgG1 protein samples, hIgG1acceptor beads, and GST-FcgRIIa, or GST-FcgRIIIa, were incubated for 2 hours in the dark
with shaking at 22° C. All reagents were diluted in binding assay diluent. Plates were read
on EnVision Multilabel 2101, (Perkin Elmer, Waltham, MA). Each sample was tested in
triplicates. Parallel Line Analysis software (Stegmann Systems, Germany) was used to
assess the linearity, parallelism, and potency of the sample in relation to a reference
standard.
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3.8

Tables

Table 3.1. Relative levels of oxidation and deamidation of Lys-C peptide fragments.
Met83/
Peptide #

Met34

Met111

Met259

Asn322

Met365

Met435

Unmodified IgG1

0.0%

2.5%

10.1%

2.4%

1.7%

6.6%

Reaction Control IgG1

0.0%

3.6%

10.3%

2.7%

2.4%

7.2%

Hypersialylated IgG1

0.0%

3.8%

12.6%

3.9%

3.0%

5.1%

Hypergalactosylated IgG1

0.0%

4.5%

14.3%

3.9%

3.0%

10.7%

Deglycosylated IgG1

0.0%

1.4%

6.8%

9.6%

1.0%

3.6%

Table 3.2. Relative abundance of various glycoforms present within the only glycopeptide
ion (L19/20) detected in the entire complement of Lys-C peptide fragments.
Peptide #

G0

G1

G2

G2+SA G2+2SA

Unmodified IgG1

59.5% 36.4%

4.1%

0.0%

0.0%

Reaction Control IgG1

64.6% 32.0%

3.4%

0.0%

0.0%

Hypersialylated IgG1

0.0%

0.0%

0.0%

62.6%

37.4%

Hypergalactosylated IgG1

0.0%

0.0%

100.0%

0.0%

0.0%

Deglycosylated IgG1

0.0%

0.0%

0.0%

0.0%

0.0%
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Table 3.3. Values of kon, koff, and KD for IgG1/FcRn interactions calculated from the
biolayer interferometry assay.
Sample

KD (M)

kon(1/M*s)

koff(1/s)

% Change

Unmodified IgG1

4.8E-09

9.2E+05

4.5E-03

100%

Reaction Control IgG1

4.7E-09

8.9E+05

4.2E-03

103%

Hypersialylated IgG1

4.0E-09

8.5E+05

3.4E-03

122%

Hypergalactosylated IgG1

4.4E-09

8.5E+05

3.7E-03

110%

Deglycosylated IgG1

5.9E-09

9.0E+05

5.3E-03

83%

Table 3.4. Retention time, %HMW, and %HMW change (as compared to unmodified
IgG1) for each IgG1 sample.
Sample
Unmodified IgG1
Reaction Control IgG1
Hypersialylated IgG1
Hypergalactosylated IgG1
Deglycosylated IgG1

Ret. Time (min)
9.74
9.78
9.77
9.79
9.76
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%HMW
0.6%
0.6%
0.2%
0.3%
1.1%

%HMW Increase
-0.0%
-0.4%
-0.3%
0.5%

3.9

Figures

Asn297
Asn330
Met252
Met428

Figure 3.1. Schematic representation of IgG1 architecture based on 1HZH scaffold. The
light chain is colored in red and the heavy chain is colored in blue (with FcRn binding
interface highlighted in purple and FcRγ in cyan). The glycan chain is shown in spherical
representation, and the secondary structure of the polypeptide chains is shown using
common notations (strands, turns and helices). The side chains of two methionine residues
and one asparagine residue prone to non-enzymatic PTM as shown in spherical
representation.
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Figure 3.2. Deconvoluted mass spectra of intact (blue), fully-deglycosylated (black),
hypergalactosylated (yellow), and hypersialylated (magenta) forms of IgG1. The inset
shows the structure of the glycan chain.
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Figure 3.3. Extracted ion chromatograms for the two peptide ions representing intact
(black) and oxidized (red) forms of Met252 (the corresponding mass spectra are shown in
the inset). The peptides were produced by Lys-C digestion of the control (left panel) and
hypersialylated IgG1 samples.
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d2(OD normalized)/d(nm)2

wavelength, nm
Figure 3.4. Plots of second derivatives of near-UV absorption spectra of intact (blue),
fully-deglycosylated (black), hypergalactosylated (yellow), and hypersialylated (magenta)
forms of IgG1. The inset shown distribution of aromatic residues within the IgG1 structure
using 1HZH as a scaffold.
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Cp, kCal/(mol.K)

Tm2/3

Tm1

Temperature, oC
Figure 3.5. Overlay of DSC thermograms for intact (blue), fully-deglycosylated (black),
hypergalactosylated (yellow), and hypersialylated (magenta) forms of IgG1 samples. Tm1
and Tm2/3 correspond to the CH2 and combined CH3/Fab melting points respectively.
Deglycosylated IgG1 showed a decrease of its Tm1 which has been previously reported.
Hypersialylated IgG1 is observed to have a global decrease of its melting points.
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nm shift
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Figure 3.6. FcRn binding and dissociation curves for intact (blue), fully-deglycosylated
(black), hypergalactosylated (yellow) and hypersialylated (magenta) forms of IgG1
obtained with a biolayer interferometry assay at 4.17, 8.33 nM, 16.7 nM, and 33.3 nM.
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Figure 3.7. Bar graphs for intact (blue), reaction control (red), fully-deglycosylated
(black), hypergalactosylated (yellow) and hypersialylated (magenta) forms of IgG1
binding to FcRn. Error bars correspond to the 95% confidence interval of each
measurement. FcRn relative potency: intact (100%), reaction control (111%), fullydeglycosylated (58%), hypergalactosylated (82%) and hypersialylated (98%)
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Figure 3.8. Bar graphs for intact (blue), reaction control (red), fully-deglycosylated
(black), hypergalactosylated (yellow) and hypersialylated (magenta) forms of IgG1
binding to FcgRIIA (top) and FcgRIIIA (bottom). Error bars correspond to the 95%
confidence interval of each measurement. FcgRIIA/ FcgRIIIA relative potency: intact
(100%/100%), reaction control (106%/104%), fully-deglycosylated (N.B./N.B.),
hypergalactosylated (77%/109) and hypersialylated (95%/119%)
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3.10 Supplemental Figures
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Figure S3.1. Naming convention for all observed carbohydrate chains attached to IgG1.
G0/G0 is the core moiety of a complex glycan chain.
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Figure S3.2. Intact (blue), reaction control (green), hyper-galactosylated (yellow), and
hyper-sialylated (magenta) forms of IgG1 samples were deglycosylated and two charge
states (+65/64) were looked at to assess if there increases of PTMs (glycation and
oxidation).
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Figure S3.3. Representative extracted ion chromatograms and mass spectra for
G0/G1/G2 glycopeptides.
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CHAPTER 4
INTEGRATION OF ON-COLUMN CHEMIAL REACTIONS IN PROTEIN
CHARACTERIZATION
This chapter has been adapted from a paper submitted as: Pawlowski, J., Carrick, I. &
Kaltashov, I. A. Integration of on-column chemical reactions in protein characterization
by LC/MS: cross-path reactive chromatography. Anal. Chem.,
doi:10.1021/acs.analchem.7b04328 (2018).

4.1

Abstract
Profiling of complex proteins by means of mass spectrometry (MS) frequently

requires that certain chemical modifications of their covalent structure (e.g., reduction of
disulfide bonds) be carried out prior to the MS or MS/MS analysis. Traditionally, these
chemical reactions take place in the off-line mode to allow the excess reagents (the majority
of which interfere with the MS measurements and degrade the analytical signal) to be
removed from the protein solution prior to MS measurements. In addition to a significant
increase in the analysis time, chemical reactions may result in a partial or full loss of the
protein if the modifications adversely affect its stability, e.g. making it prone to
aggregation. In this work we present a new approach to solving this problem by carrying
out the chemical reaction on-line using the reactive chromatography scheme on a sizeexclusion chromatography (SEC) platform with MS detection. This is achieved by using a
cross-path reaction scheme, i.e. by delaying the protein injection onto the SEC column
(with respect to the injection of the reagent plug containing a disulfide-reducing agent),
which allows the chemical reactions to be carried out inside the column for a limited (and
precisely controlled) period of time, while the two plugs overlap inside the column. The
reduced protein elutes separately from the unconsumed reagents, allowing the signal
suppression in ESI to be avoided and enabling sensitive MS detection. The new method is
used to measure fucosylation levels of a plasma protein haptoglobin at the whole protein
level following on-line reduction of disulfide-linked tetrameric species to monomeric units.
The feasibility of top-down fragmentation of disulfide-containing proteins is also
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demonstrated using β2-microglobulin and a monoclonal antibody (mAb). The new on-line
technique is both robust and versatile, as the cross-path scheme can be readily expanded to
include multiple reactions in a single experiment (as demonstrated in this work by
oxidatively labeling mAb on the column, followed by reduction of its disulfide bonds and
MS analysis of the extent of oxidation within each chain of the molecule).

4.2

Introduction
Analysis of protein covalent structure (which includes both amino acid sequence

and post-translational modifications, PTMs) is now routinely carried out using LC/MS and
LC/MS/MS. While comprehensive structural analyses have traditionally relied upon the
so-called “bottom-up” approach, where proteolysis precedes the LC/MS step, analysis of
the whole protein provides an attractive alternative as it allows valuable protein
characteristics (including information on structural heterogeneity) to be obtained without
requiring time-consuming proteolytic steps.1 Furthermore, the progress made in recent
years in the field of top-down MS2 resulted in a dramatic expansion of the range of proteins
amenable to analysis by this technique.3-6
By eliminating the need for proteolysis, top-down MS not only simplifies the
sample handling step, but also greatly reduces the possibility of introducing artifacts.7-10
One serious impediment that frequently complicates the top-down analysis of protein
structure is the presence of multiple disulfide bonds. Indeed, even though dissociation of
the thiol-thiol linkages can be achieved in the gas phase by using electron-based ion
fragmentation techniques,11 negative-ion CID12 or ultra-violet photo-dissociation
(UVPD),13 these approaches typically work for small proteins14 or peptides,15 while larger
proteins with multiple intact disulfide bonds remain out of reach of these techniques.
Therefore, it is not surprising that in most cases successful top-down analysis of
biopharmaceutical products relies on disulfide bond reduction prior to MS/MS
measurements, which can be done using either conventional chemical reduction methods4
or electrochemical cells interfaced with MS.16,17 Above and beyond top-down MS/MS
analysis of protein structure, reduction of disulfides prior to MS measurements may prove
beneficial for other analytical tasks. For example, complexity and heterogeneity of
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recombinant proteins, protein/drug conjugates and endogenous macromolecules used as
biomarkers can frequently be assessed by measuring their masses (or, more precisely,
distribution of molecular masses in analytical and/or clinical samples).1 While this task can
be readily accomplished using modern MS tools for proteins with relatively low degree of
complexity, it becomes increasingly challenging as both the size and the degree of
heterogeneity increase.
One of the most significant sources of heterogeneity of many proteins is their
glycosylation, the most abundant type of post-translational modifications (PTMs) found in
both membrane and secreted proteins.18 Glycosylation patterns frequently have a
tremendous diagnostic value, holding enormous promise in the emerging field of
personalized medicine.18 Indeed, carbohydrate composition is known to be modulated not
only by congenital disorders that affect the glycosylation machinery at the genetic level,19
but also by a variety of other pathologies, including Alzheimer’s disease and other
cognitive disorders,20 diabetes,20 immune disorders,21 and cancer.18,22
The use of biomarkers in personalized medicine can be quite complicated, since
frequently it is a panel of biomolecules, rather than a single reporter molecule, that needs
to be considered. Therefore, sophisticated mathematical tools, such as multivariate
statistical analysis,23 are commonly used in order to provide meaningful results.
Fortuitously, a number of serum glycoproteins offer unique opportunities for streamlined
cancer diagnosis by exhibiting disease-specific glycosylation patterns.24 Traditionally,
protein glycan analysis is carried out in the bottom-up fashion, by isolating the protein of
interest followed by enzymatic removal of the glycans and their analysis by MS and/or
MS/MS.22 Alternatively, composition of glycans can be established in favorable cases by
the analysis of the intact protein mass,25 bypassing the enzymatic step. Unfortunately, this
approach is feasible only when applied to proteins with a relatively low extent of
glycosylation (such as IgG molecules25), while extensive glycosylation inevitably results
in high levels of heterogeneity preventing meaningful mass profiling.26 In many cases,
however, the extent of heterogeneity can be reduced to allow meaningful MS
measurements without compromising the information encoded by glycans. For example, a
number of plasma glycoproteins with high diagnostic value (haptoglobin and complex
immunoglobulins) are multi-unit assemblies linked by disulfide bonds. Reduction of the
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thiol-thiol linkages may produce monomeric glycoproteins that can be readily massprofiled by MS at the whole protein level, while their glycosylation patterns remain
preserved. Unfortunately, such monomeric units are frequently only marginally stable and
readily aggregate/precipitate prior to MS analysis.
Above and beyond disulfide reduction, a variety of other chemical reactions are
used to probe biopolymer structure, e.g. selective chemical labeling and cross-linking.27,28
Top-down MS offers an elegant way to determine the chemically modified and crosslinked sites in biopolymer complexes,29 but it cannot be applied directly to analyze
modified proteins in reaction mixtures without removing all unconsumed reagents and/or
quenching agents that are incompatible with the ESI process. The clean-up step not only
increases the analysis time and cost, but can also lead to the protein loss should
modifications render it less stable. Clearly, there is an urgent need for an experimental
scheme eliminating the clean-up step and enabling protein MS characterization in an online fashion immediately following the completion of the chemical transformations.
The goal of this work is to explore the possibility of carrying out chemical reactions inside
a chromatographic column as a means of combining protein modification and MS analysis
in a one-step experiment. Reactions taking place inside chromatographic columns are
commonly viewed as detrimental (e.g., reactions between the analyte and the mobile phase
components giving rise to artifacts30). However, there are applications where on-column
reactions are carried out intentionally in order to enhance the analyte detection while
maintaining the separation fidelity (e.g., on-column derivatization with chromophores to
enable spectrophotometric detection in LC31,32 or with ionizable groups to enhance
detection in GC/MS33). Integration of certain reactions with the separation process (e.g.,
acid/base reactions,34 as well as a combination of metal ion complexation and redox
reactions

35-37

) may also improve the LC separation selectivity. Finally, integration of

chemical reactions with chromatographic separation can also be used to study organic
reaction mechanisms.38,39
Recently, on-column chemical reactions were used to enhance the quality of
biopharmaceuticals by converting trisulfide bonds to disulfides within a monoclonal
antibody (mAb) captured by an affinity column.40 Affinity capturing is a reliable way of
retaining a protein while carrying out modifications that do not disrupt its native structure.
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However, this approach is too restrictive with regards to the types of chemical reactions.
Indeed, this scheme would not allow incorporation of chemical reactions altering the higher
order structure (i.e., conformation and/or quaternary assembly), nor would it be tolerant to
denaturing solvents. More importantly, on-column reactions are likely to target the affinity
ligand in addition to captured analytes, thereby compromising the analyte retention and
damaging the column. Lastly, even though affinity separation of immunoglobulins is now
a routine procedure due to the availability of a wide range of antibody-specific ligands,41,42
high-affinity ligands for other proteins may not be available as readily.
Since our goal was to devise a versatile experimental scheme allowing a variety of chemical
reactions to be carried out on the column, we focused our attention on methods of
separation that utilize stationary phases remaining inert towards protein-modifying agents,
such as size exclusion chromatography (SEC). Since the majority of biomolecules cannot
be permanently captured in SEC, we adopted a cross-path scheme: injection of the fastmoving protein molecules is delayed with respect to the loading of slow-moving chemical
regents; the chemical reactions occur inside the column during the time interval when the
reagent and protein plugs overlap (Figure 4.1). This separates the chemically modified
protein upon its elution from the unconsumed reagents, enabling on-line protein analysis
by MS. The feasibility of this approach is demonstrated by carrying out on-column
reduction of several disulfide-containing proteins. The new method of protein structure
analysis (dubbed XP-RC/MS, or cross-path reactive chromatography with MS detection)
can be expanded to accommodate multiple reactions in a single experiment (demonstrated
in this work by oxidative labeling of mAb, followed by reduction of its disulfide bonds and
MS analysis of each immunoglobulin chain).
4.3

Experimental
Materials. Haptoglobin 1-1 (Hp) was purchased from Athens Research (Athens,

GA); b2-microglobulin (β2m) was purchased from Lee Biosolutions (Maryland Heights,
MO), and the mAb sample was generously provided by Biogen (Cambridge, MA). PNGase
F (500,000 U/mL) was purchased from New England Biolabs (Ipswich, MA). Hydrogen
peroxide (30%), ammonium acetate (HPLC grade), Tris and TCEP were purchased from
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Thermo-Fisher Scientific (Hampton, NH). All solvents and chemicals were of analytical
grade or higher.
Deglycosylation of mAb. The mAb sample was buffer exchanged into 100 mM Tris buffer
(pH 7.5) followed by pipetting solution containing 25 mg of mAb (by dry weight) into a
vial and diluted up to 990 µL with 100 mM Tris buffer (pH 7.5). A 10 µL aliquot of PNGase
F was added to the vial, followed by incubation in a water bath at 37 OC. After incubation,
deglycosylated IgG1 was buffer exchanged into a 150 mM ammonium acetate solution and
stored at 2-8 OC.
On-column protein modification. On-column chemical reactions were carried out
on a TSKgel SuperSW mAb HTP (Tosoh, Tokyo, Japan) SEC column used with an HP
1100 (Agilent, Santa Clara, CA) HPLC system. A 75 mM ammonium acetate solution (pH
5.5) at a flow rate of 0.15 mL/min was used as a mobile phase for the analysis of Hp
glycosylation patterns; a 150 mM ammonium acetate solution (pH 3.0) at a flow rate of 0.1
mL/min was used as a mobile phase for the top-down β2m analysis; and a 9:1 (v:v) mixture
of aqueous 75 mM ammonium acetate solution (pH 3.0) with acetonitrile at a flow rate of
0.15 mL/min was used as a mobile phase for the structural analyses of deglycosylated mAb.
The reduction plugs were composed of 100 mM TCEP (β2m analysis), 50 mM TCEP and
4M guanidinium chloride (Hp analysis); and 0.5 M TCEP and 5M guanidinium chloride
(mAb analyses) in their respective mobile phases. The plugs were introduced using a
manual injector with a loop volume of 100 µL (β2m) and 150 µL (mAb and Hp), which
was placed between the sample injector and the SEC column. The protein samples were
injected with a delay time of 10 sec (β2m) or 1 min (mAb and Hp) following the reagent
plug injection.
Sequential on-column reactions (oxidation followed by disulfide reduction) were
carried out with a TSKgel 3000SW xl (Tosoh, Tokyo, Japan) SEC column used with an
HP 1100 HPLC system. A 75 mM ammonium acetate solution (pH adjusted to 3.0) with
10% methanol at a flow rate of 0.5mL/min was used as a mobile phase for the analysis of
deglycosylated mAb. A flow splitter was used to send ~10% of the flow to the mass
spectrometer and the rest to waste. The oxidation plug was composed of 2% hydrogen
peroxide, 10% methanol, and 75 mM ammonium acetate (pH 3.0). The reduction plug was
composed of 100mM TCEP, 10% methanol, and 75 mM ammonium acetate (pH 3.0).
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Each plug was introduced using a manual injector with a loop volume of 250 µL. The
reduction and oxidation plugs were injected three and one minute prior to deglycosylated
mAb injection, respectively.
MS Measurements and data analysis. All MS and MS/MS measurements were
performed with a SolariX 7 (Bruker Daltonics, Billerica, MA) Fourier transform ion
cyclotron resonance (FT ICR) mass spectrometer equipped with a 7.0 T superconducting
magnet and a standard ESI source. Protein ions at successive charge states +11 through
+14 (β2m) and +12 through +16 (mAb light chain) were isolated in the front-end
quadrupole for MS/MS measurements; collision-induced dissociation (CID) in the
hexapole region was used to induce ion fragmentation. The excitation voltage was set for
at 22V and 30V for β2m and mAb light chain ions, respectively. MS/MS data were
analyzed with DataAnalysisTM and BioToolsTM software packages (Bruker Daltonics,
Billerica, MA); all assignments made by BioToolsTM were manually inspected to eliminate
a possibility of false positives.
4.4

Results and Discussion
Feasibility of using on-column reactions in LC/MS: XP-RC MS profiling of

haptoglobin. Haptoglobin 1-1 (Hp) is a plasma glycoprotein composed of four subunits
(two heavy chains, H, and two light chains, L) connected by disulfide bonds as H-L-L-H.43
There are eight glycosylation sites within this protein (residing exclusively within the H
chains), making the carbohydrate content of this protein nearly 20% of the total mass (92
kDa). Such a significant extent of glycosylation gives rise to a high level of structural
heterogeneity making it nearly impossible to obtain reliable MS measurements.26 Indeed,
even though an SEC/MS spectrum of intact Hp contains abundant ionic signal (Figure
4.2A, B), the peaks representing different charge states are broad and do not show distinct
contributions from individual glycoforms. This makes it impossible to deduce any
meaningful information on the composition of Hp glycans. Reduction of disulfides would
be an obvious approach to glycoform profiling at the intact polypeptide level (it should
produce monomeric H-chains with a mass of only 37 kDa) and lower the extent of
glycosylation (four glycans per each H-chain). However, these monomeric species become
unstable upon disulfide reduction, and aggregate readily during a buffer exchange step

105

preceding MS analysis. The new approach to disulfide reduction explored in this work (oncolumn chemistry followed by on-line MS detection) minimizes the time between the
protein reduction and the MS measurement and provides an opportunity to vary it from
tens of seconds to several minutes by selecting an appropriate delay for protein injection
(Figure 4.1). Increasing this delay decreases the time period spent by the metastable
chemically modified species inside the column, dramatically reducing the specter of oncolumn aggregation.
On-column reduction (with TCEP used as a reducing reagent) gives rise to an
abundant ionic signal of L-chains (12 min elution) and H-chains (11 min) in SEC/MS
(Figure 4.2C). The reduction is incomplete, as evident by the presence of covalent dimers
L2. We also note that limited aggregation of metastable polypeptides does occur, as
evidenced by the SEC peak at 8 min. elution (no interpretable ionic signal could be obtained
for these high molecular weight species). This highlights the intrinsic instability and
aggregation propensity of monomeric H-chains. Nevertheless, the abundance of both Land H-chains ions in the mass spectra collected at longer elution times (11-12 min) is high,
allowing the assignment of all eluting species to be readily made based on their masses. In
a stark contrast to intact Hp, ionic signal of monomeric H-chains displays a number of
baseline-resolved peaks representing different glycoforms (Figure 4.2D). Measuring the
mass differences between adjacent peaks allows three major clusters to be identified (as
labeled in Figure 4.2D). The mass difference between the clusters corresponds to a
segment comprising a GlcNAcGalNeuAc trisaccharide (N-acetyl-glucosamine, galactose,
and N-acetylneuraminic acid). The spacing between adjacent peaks within each cluster
corresponds to a fucose residue mass (142.1 Da), with the total level of fucosylation
ranging from zero to four (as indicated in Figure 4.2D). Fucosylation patterns are highly
reproducible, allowing the extent of fucosylation to be calculated with an error not
exceeding 9% RSD (see Supporting Information). Therefore, XP-RC MS provides a
means of exploiting the high diagnostic value of Hp fucosylation patterns without the need
to remove/isolate carbohydrate chains from the protein. Sufficient amounts of monomeric
species are produced during Hp transient exposure to the reducing agent (TCEP) inside the
column, while the cross-path scheme eliminates any interference from TCEP during the
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on-line MS analysis of these monomeric polypeptides: the reagent plug does not emerge
from the column until after all Hp components have eluted (Figure 4.2A).
Top-down sequencing of small disulfide-containing proteins: XP-RC MS/MS
analysis of β2-microglobulin. Despite its modest size (11.7 kDa), β2m presents a challenge
for top-down MS/MS analysis. Its single disulfide bridge (Cys25-Cys80) exerts a two-fold
negative effect on the diagnostic value of the top-down MS/MS data. First, collisioninduced dissociation (CID) of the peptide bonds within the [Cys25-Cys80] segment does not
give rise to observable fragment ions (the two fragments are still physically connected by
the thiol-thiol linkage, and the mass of this dimer is indistinguishable from that of intact
protein ions). Indeed, all CID-generated b- and y-fragments of β2m with the intact disulfide
are confined to the short terminal segments of the polypeptide, [Ile1-Cys25] and [Cys80Met99] (see Supporting Information). Second, the presence of the disulfide cross-link
within the polypeptide chain results in a significant reduction of the conformational space
it can sample in solution even under denaturing conditions. Since the physical size of the
protein is the major determinant of the extent of its multiple charging in ESI,44,45 the
number of charges accommodated by β2m ions with the intact disulfide bridge will remain
modest, limiting the collision energy. The highest charge state observed for β2m ions in
conventional SEC/MS is +10; and the efficiency of cumulative CID of four precursor ions
(from +7 to +10) is rather modest (see Supporting Information).
In contrast, the extent of multiple charging of polypeptide ions produced by ESI
following the on-column disulfide reduction is relatively high (extending up to a charge
state +17, see Supporting Information). In addition to the dramatic change in the protein
ion charge state distribution, disulfide reduction also manifested itself by a mass increase
of 2 Da for ions at lower m/z. Mass increase for ions at lower charge states (<+9) was also
evident, although the overall shift was less than 2 Da, indicating the presence of both
disulfide-reduced and surviving disulfide-intact proteins. CID of ions corresponding to the
disulfide-reduced β2m (charge states +11 through +15 were selected as precursors) gives
rise to a large number of fragments (see Supporting Information). In addition to a
significant gain in the overall intensity of fragment ions, the fragmentation pattern also
changes dramatically, with half of the observed fragment ions resulting from amide bond
cleavages within the [Cys25-Cys80] segment, which failed to generate distinguishable
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fragment ions without on-column protein reduction. Clearly, on-line reduction of β2m
results in a dramatic increase of the quality of information that can be extracted from the
top-down MS/MS measurements while minimizing both sample preparation and analysis
time.
Top-down analysis of a disulfide-connected protein assembly’s subunit: on-line
mAb’s light chain analysis. While the XP-RC MS/MS analysis of β2m yields sequence
information not accessible via CID of the disulfide-intact protein, it should be remembered
that β2m is a rather modest protein whose single disulfide bond can be cleaved in the gas
phase using electron capture dissociation.14 The vast majority of biopharmaceuticals are
significantly larger and contain multiple disulfide bonds (which could both reinforce the
conformation of a single polypeptide chain by providing intra-chain cross-links, and
connect several monomeric units in a multi-unit assembly). These features are epitomized
by mAbs, recombinant proteins based on the IgG1 structural template.
There are sixteen disulfide bonds in the mAb used in our work. This includes twelve
internal thiol-thiol connections, two in each of the light chains (L) and four in each of the
heavy chains (H), and four inter-chain linkages (with each L/H pair being connected by a
single disulfide bond, and the remaining two thiol-thiol linkages connecting the two Hchains). The inter-chain bonds are more labile, as they can be reduced under native
conditions, when the intra-chain bonds remain intact.46 Since our goal was to explore the
utility of top-down MS for structural characterization of mAbs, we used low-pH conditions
to maximize the reduction of all disulfide bonds. The chromatogram of mAb that
underwent on-column reduction has a convoluted shape; on-line MS analysis reveals the
presence of both monomers (L and H) and incompletely reduced assemblies (HL, H2 and
H2L), see Supplementary Material for more detail.
While the effective reduction of external disulfide bonds in XP-RC is evident due
to the presence of L- and H-chain ions, mass spectra acquired on-line do not produce direct
evidence that the on-column reduction also succeeded in eliminating the internal disulfide
bonds. Some indirect evidence is provided by the charge state distributions of the L- and
H-chain ions. Indeed, the bimodal character of the charge state distributions, as well as the
presence of ionic species with high charge density (in the low m/z regions of the spectra)
suggest that at least some internal disulfides have been reduced. In order to determine if

108

any internal disulfide bonds were indeed eliminated as a result of the on-column reduction,
on-line MS/MS analysis of the L-chain was carried out. Five charge states (+16 through
+12) were mass-selected as precursors for CID. The presence of 5 M guanidinium chloride
in the reagent plug results in the most facile fragmentation (as judged by both overall
intensity of the fragment ions and the number of amide bonds undergoing dissociation, see
Figure 4.3 and Supplementary Material). The detected high-abundance fragment ions
(both b- and y-type) correspond to cleavages of nearly half of the amide bonds within the
constant region of the L-chain (fifty-two out of one hundred and thirteen).
Guanidinium chloride is a very effective chaotrope frequently used as a protein
unfolding agent. Its presence in the reagent plug likely results in more efficient unfolding
of mAb chains, exposing the disulfide bonds to the reducing agent. Guanidinium chloride
cannot be used in ESI MS measurements; however, in our scheme this interference is
eliminated by separating polypeptide chains from the chaotrope prior to MS analysis.
Importantly, twenty fragment ions detected in the XP-RC/MS/MS analysis of the L-chain
correspond to the region of the polypeptide chain flanked by two cysteines (Cys134 and
Cys194) forming an internal disulfide bond (Figure 4.3). This provides unequivocal
evidence that this internal disulfide had been successfully eliminated during protein
exposure to the reagent plug inside the column. A comparable sequence coverage was
obtained in XP-RC MS/MS measurements in the absence of guanidinium chloride in the
reagent plug, but the overall abundance of the fragment ions was noticeably lower (see
Supplementary Material). As an alternative approach to MS/MS, in-source fragmentation
of ions without mass selection was carried out within the time window corresponding to
the elution of L-chains (14-20 min, see Supplementary Material for more detail). Although
the total fragment ion abundance was lower compared to the on-line MS/MS experiments,
the extent of the sequence coverage was comparable, suggesting that XP-RC MS can be
implemented on inexpensive MS platforms lacking tandem capabilities.
Since the presence of guanidinium chloride appears to favor dissociation of
disulfide bonds, it seems reasonable to assume that other chaotropic agents may also prove
beneficial as far as breaking thiol/thiol linkages. One particularly attractive possibility lies
with the use of co-solvents that do not have to be confined to the reagent plug, but instead
can be used as a part of the mobile phase. For example, addition of alcohols to the mobile
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phase is likely to destabilize the tertiary structure of the proteins, while keeping the
secondary structure largely intact. This should increase the solvent exposure of disulfide
bridges (and, therefore, reduction efficiency) without raising the specter of protein
aggregation. Indeed, addition of even relatively modest amount of methanol to the mobile
phase (10% by volume) results in a notable decrease of the relative abundance of all
partially reduced species (H2L, H2, and HL), and near-complete elimination of the ionic
signal of the surviving intact assembly H2L2 (see Supplementary Material for more detail).
An important question that should be addressed in connection with the on-column disulfide
reduction is the possibility of recombination of free thiol groups outside of the reagent plug.
Should this process occur, it would lead to (re)formation of disulfides prior to MS/MS
detection. Above and beyond its obvious negative effect on the overall efficiency of the
XP-RC process, thiol/thiol recombination can give rise to artifacts (e.g., formation of
disulfide bonds that were not present in the original protein). We note, however, that all
multimeric species observed in the XP-RC MS of the mAb sample appear to be
“legitimate” products of partial disulfide reduction (e.g., H2L, H2, and HL), while any signs
of de novo disulfide formation are absent (e.g., HL2, L2, etc.). This provides a reasonable
assurance that no disulfide recombination occurs under the conditions employed in XP-RC
measurements following the on-column disulfide reduction.
It is interesting to compare the results of XP-RC/MS/MS analysis of mAb in this
work with the top-down characterization of IgG molecules carried out using common
approaches. Due to their large size, structural analyses of antibodies by MS until recently
were almost exclusively carried out using the bottom-up approaches, where gas-phase
fragmentation is preceded by proteolysis in solution. This is now beginning to change
mainly due to the rapidly increasing demands for the high-throughput analysis of mAbs
and mAb-related products in the biopharmaceutical sector, with several groups actively
exploring the feasibility of the top-down approach.6,16,47 Not surprisingly, intact disulfide
bonds present a formidable problem for the top-down analysis of mAb: while electronbased ion dissociation techniques allow some thiol-thiol linkages to be cleaved in the gas
phase, the large number of disulfides typically present in mAbs limits the number of
fragment ions derived from polypeptide segments flanked by disulfide-connected cysteine
residues.47 Chemical reduction of disulfides prior to antibody analysis by top-down MS

110

results in a dramatic increase of the number of structurally diagnostic fragments and the
extent of sequence coverage. Interestingly, sequence coverage of the variable regions is
highly antibody-specific. For example, Marshall and co-workers observed that despite the
88% sequence identity between the variable domains of the light chains of Adalimumab
and Efalizumab, the sequence coverage in this region differed by nearly six-fold, while the
coverage of the constant regions was nearly identical between the two antobodies.6
Therefore, a meaningful comparison of two different techniques vis-à-vis the extent of
mAb sequence coverage should focus on the constant (κ) region, rather than compare the
overall sequence coverage across the entire polypeptide chain. The number of the amide
bonds within the constant region of mAb light chains that dissociate under ETD/CID
combination giving rise to structurally diagnostic fragment ions reported by Marshall and
co-workers for disulfide-reduced proteins is 61-62.6 This number far exceeds the extent of
sequence coverage that can be obtained without the reduction step prior to dissociation (up
to 23 for the same segment47), but is comparable with that obtained in XP-RC MS/MS
experiments (50 in the constant region of the light chain, as shown in Figure 4.3).
Interestingly, the fragmentation efficiency of the light chain of a mAb molecule subjected
to the top-down MS/MS analysis following the on-line reduction in an electrochemical cell
was relatively modest in comparison: even though the intra-chain disulfides were
successfully reduced, the number of structurally diagnostic fragments derived from the
light chain was relatively low, and their localization within the sequence was consistent
with the notion of the internal thiol-thiol linkages remaining intact.16 Clearly, XP-RC MS
appears to be a more robust method for on-line reduction coupled to top-down MS analysis
of monoclonal antibodies. Another important advantage offered by this technique is its
versatility, as it allows various types of chemical modifications to be carried out prior to
MS analysis (vide infra). Furthermore, multi-step modification procedures can be
implemented in a single experiment, as outlined in the following section.
Feasibility of using multiple reactions in XP-RC MS: sequential on-column
oxidative labeling of mAb and reduction of disulfide bonds. All examples of protein
analysis with XP-RC MS considered so far utilize a single reagent plug. However, one can
envision using multiple plugs containing different reagents in a single experiment. As long
as all reagents fall under the permeation limit, the plugs will travel inside the SEC column
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along parallel trajectories, and the protein injected with a delay will be exposed to these
reagents in a sequential manner (Figure 4.4). This would provide an opportunity to expand
the use of XP-RC MS to probing higher order structure of proteins and protein assemblies,
e.g. by employing chemical labeling as a probe of solvent accessibility.48 The feasibility of
this approach was evaluated using a scheme depicted in Figure 4.4, where oxidative
labeling of mAb was carried out by using a plug of a 2% H2O2 solution, followed by
exposure of the labeled protein to the TCEP plug. The ensuing disulfide dissociation
generates L- and H-chains along with partially reduced species (H2L, H2, and HL), as
previously observed in a “single-reaction” XP-RC MS/MS analysis of mAb. On-line MS
detection provides clear evidence for the three oxidation events occurring within the Hchain (manifested by a mass shift of 50±2 Da), but not in the L-chain (see the top panels in
Figure 4.4). The mass shifts observed within the partially reduced species and the intact
assembly are also consistent with the notion of the H-chain undergoing oxidation at three
sites, while the L-chain does not suffer any oxidative damage (48±3 Da shift for HL, 97±2
for H2, and 98±3 for H2L).
While H2O2 is hardly the best choice as a labeling reagent in terms of its efficiency with
respect to protein labeling and the effect on the column longevity, the multiple reaction
XP-RC scheme can be used for probing higher order protein structure with a variety of
labeling reagents in the first plug, including amino-acid specific labeling reagents.27
Another application where the multiple-reaction feature of XP-RC MS will be
advantageous is the ranking of disulfide susceptibility to reduction using isotopically
labeled thiol-capping reagents.49
4.5

Conclusions
Top-down MS analysis of proteins is a powerful tool for elucidation of various

aspects of both covalent50-52 and higher order structure.53-56 Many applications of top-down
MS require chemical treatment of proteins prior to MS analysis, which inevitably
introduces ESI-incompatible low-molecular weight components (unconsumed reagents,
quenchers, etc.) that must be removed prior to the MS analysis. This creates problems for
proteins where the chemically modified forms are metastable and undergo
aggregation/precipitation during the sample clean-up step. Furthermore, even for proteins
that remain stable throughout the clean-up step, the latter results in a significant increase
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of the sample handling/analysis time. The cross-path reactive chromatography (XP-RC)
presented in this work as a means of facilitating top-down MS protein analysis solves this
problem by initiating the chemical transformations inside the chromatographic column,
and separating the high-molecular weight products (modified proteins) from the lowmolecular weight reagents prior to the on-line MS analysis.
In this initial report we focus primarily on disulfide reduction as a means of
increasing the value of information provided by on-line MS and MS/MS measurements for
proteins that have traditionally been challenging for the top-down MS analysis. This new
approach offers a straightforward way to control the extent of chemical modifications by
varying either the width of the reagent plug or the reagent concentration (or both). It also
provides a means of controlling the undesirable post-reaction processes (e.g., aggregation
of metastable chemically modified species) by allowing the time interval between the
analyte’s exposure to the regent plug and its elution from the column to be minimized by
selecting an appropriate injection delay. An additional benefit offered by this technique is
the (partial) separation of the reaction products, which allows the spectral crowding to be
reduced and the quality of the MS data to be enhanced.
Above and beyond disulfide reduction, XP-RC allows other reactions to be
implemented, including those that can be used to probe protein higher order structure. In
some ways, the cross-path scheme presented in this work resembles the “catch-me-if-youcan” approach introduced by Krylov and co-workers as a means to measure kinetics of
non-covalent interactions of proteins with small ligands.57 A unique advantage of the crosspath scheme demonstrated in our work is the possibility of carrying out multiple reactions
in sequence during a single experiment (e.g., oxidative labeling followed by disulfide
reduction to assist on-line MS characterization). Lastly, even though all experiments
presented in this work had been carried out using SEC, the XP-RC methodology can be
implemented on a variety of other LC platforms, provided the chemically treated protein(s)
can be separated from the unconsumed reagents prior to the on-line MS analysis (we are
currently exploring the utility of ion exchange chromatography for this purpose)
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4.7

Tables

Table 4.1. Distribution of fucosylation within the [NeuAc2Gal2Man3GlcNac4]4/Fucx
glycoforms based on the ionic peak heights in the on-line mass spectra of Hp H-chains
produced upon on-column disulfide reduction
Total number of
fucose residues
0
1
2
3
4

Relative abundance
(based on the peak
heights)
13%
12%
38%
29%
8%

95% confidence interval (based on a
set of three replicate measurements)
2%
2%
5%
3%
1%
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Figure 4.1. Schematic representation of the XP-RC using a 2-D depiction of the
chromatographic process. The numerals on the diagram indicate injection of the lowPawlowski,
et al. Figure 1
molecular weight reagent plug (0), injection of the protein (1), chemical
reaction between
the protein and the reagent (2), and elution of the unreacted protein species (3) and the
products of the chemical reaction (4 and 5).
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Figure 4.2. XP-RC MS analysis of haptoglobin 1-1. A: A UV chromatogram of a control
Hp injection without the on-column disulfide reduction (black trace) and the XP-RC
chromatogram (magenta). B: On-line mass spectrum of the control Hp injection (averaged
across the 9-10 min elution window). C: On-line mass spectra acquired in XP-RC of Hp
(the colored arrows in panel A show where the two mass spectra were acquired). D: a
zoomed view of the on-line mass spectrum of the H-chain of Hp produced by on-column
reduction. Three clusters of peaks represent the following glycoforms (based on the
measured
masses):
[NeuAc2Gal2Man3GlcNac4]4/Fucx
(black
labels),
[NeuAc2Gal2Man3GlcNac4]3/NeuAc3Gal3Man3GlcNac5/Fucx
(purple)
and
[NeuAc2Gal2Man3GlcNac4]2/[NeuAc3Gal3Man3GlcNac5]2/Fucx (gold); the numerals
indicate the number of fucose units (x) within each species.
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Figure 4.3. XP-RC MS/MS of mAb showing CID mass spectrum and fragmentation
pattern of the L-chain produced upon the on-column reduction ofPawlowski,
the intact protein.
Amino
et al. Figure
3
acid sequence is shown only for the constant region of the L-chain; the vertical lines
indicate amide bonds whose cleavage gives rise to the detected b- and y-ions (red lines
correspond to this data set; blue line correspond to XP-RC MS/MS measurements carried
out without using guanidinium chloride in the reagent plug; and black lines correspond to
fragments generated in XP-RC MS using in-source collisional activation). The inset shows
selected extracted ion chromatograms for several ionic species in XP-RC chromatogram
(reference XICs obtained in the absence of the reducing agent in the reagent plug are shown
as color-filled curves). The complete set of XICs with representative mass spectra (MS1)
is shown in the Supplementary Material section.
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Figure 4.4. A schematic diagram of an XP-RC experiment
employing
two reagent
plugs
Pawlowski,
et al. Figure
4
and the mass spectra of the constituents of mAb produced by the on-column reduction with
TCEP (reagent plug 2) following the on-column oxidative labeling with hydrogen peroxide
(reagent plug 1). The numerals on the diagram indicate injection of the protein (1),
chemical reaction between the protein and the reagent 1, e.g. oxidation with H2O2 (2),
chemical reaction between the protein and the reagent 2, e.g. reduction of disulfide bonds
(3), and elution of the unreduced (disulfide-intact) protein species (4) and the products of
the external disulfide reduction (5 and 6).
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Supplemental Figures

Figure S4.1. Reproducibility of Hp fucosylation patterns obtained with XP-RC MS
(TCEP in the reagent plug). Three different data sets are shown for the monomeric Hchain at charge state +12; labeling of individual glycoforms is the same as in Figure
4.2D.
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Figure S4.2. Isotopic distributions of β2m ions (charge states +7 and +14) produced by
XP-RC MS with TCEP in the reagent plug. Black squares in the left-hand panel show the
calculated isotopic distribution of a β2m ion at charge state +14 with a reduced disulfide
bond. The blue trace in the right-hand side diagram shows the isotopic distribution of a
β2m ion (charge state +7) produced by SEC MS (no on-column reduction).
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Figure S4.3. SEC MS/MS (top panel) and XP-RC MS/MS (bottom) analysis of β2m. The
colored traces in each panel show mass spectra of intact protein (no collisional activation),
and circles indicate protein ion used as precursors in CID measurements. The
fragmentation patterns are shown at the top of the figure for both SEC MS/MS (blue lines)
and XP-RC MS/MS (red).
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Figure S4.4. Extracted ion chromatograms for fully-, partially- and non-reduced species
of mAb detected in SEC MS without on-column reduction (filled curves) and XP-RC MS
experiments (150 mM ammonium acetate solution, pH adjusted to 3.0; TCEP in the reagent
plug). The three representative on-line mass spectra shown on the right-hand side were
averaged across the following elution windows: 14-16 min (top), 16-17 min (middle), and
17-19 min (bottom). The XICs were generated by plotting ionic signals for the following
species: H2L2, charge state +33 (m/z window 4419-4423); H2L, charge state +23 (m/z
window 5332-5336); H2, charge state +21 (m/z window 4736-4740); HL, charge state +17
(m/z window 4289-4293); H, charge state +14 (m/z window 3552-3556); and L, charge
state +9 (m/z window 2576-2580). Note that the early-eluting peaks of partially- and fullyreduced species are artifacts due to the interfering signal of the intact mAb (e.g., it is
impossible to distinguish the ionic signal of HL+17 from that of H2L2+34).
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Figure S4.5. Extracted ion chromatograms for fully-, partially- and non-reduced species
of mAb detected in SEC MS without on-column reduction (filled curves) and XP-RC MS
experiments (150 mM aqueous ammonium acetate solution, pH adjusted to 3.0, with 10%
methanol by volume; TCEP/10% methanol in the reagent plug). The three representative
on-line mass spectra shown on the right-hand side were averaged across the following
elution windows: 15-17 min (top) and 17-19 min (bottom). The XICs were generated by
plotting ionic signals for the following species: H2L2, charge state +33 (m/z window 44194423); H2L, charge state +23 (m/z window 5332-5336); H2, charge state +21 (m/z window
4736-4740); HL, charge state +17 (m/z window 4289-4293); H, charge state +14 (m/z
window 3552-3556); and L, charge state +9 (m/z window 2576-2580). Note that the earlyeluting peaks of partially- and fully-reduced species are artifacts due to the interfering
signal of the intact mAb (e.g., it is impossible to distinguish the ionic signal of HL+17 from
that of H2L2+34).
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Figure S4.6. XP-RC MS/MS analysis of mAb: fragment ion spectra of the L-chain
generated by on-column disulfide reduction of mAb (TCEP in the reagent plug).
Fragmentation was induced by collisional activation of ions of monomeric L-chains at
charge states +12 through +16 (blue-filled curve) and by collisional activation of all ions
in the ESI interface without precursor ion selection (in-source fragmentation, black trace).
The two fragmentation patterns are overlaid in the top diagram (the amino acid sequence
is shown only for the constant region of the L-chain).
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS

5.1

Conclusion
MS and LC are excellent characterization tools as demonstrated by this thesis. MS

allows for precise and accurate mass measurements that are extremely valuable for protein
identification and quality. Additionally, these measurements can be used for discovery and
quantitation of PTMs. LC provides the ability to separate components in a complex sample
by a variety of physical and chemical properties. The ability to separate proteins by a
specific property creates opportunities to tailor a method to separate out an analyte of
interest. This thesis describes a diverse set of novel LC and MS methods to analyze
proteins with biotherapeutic potential.
In chapter II, a method was developed to analyze the metal and synergistic anion
composition of Tf. LC and native MS usefulness were both highlighted with their ability
to purify and measure the composition of a non-covalent complex, respectively. To purify
Tf from serum a 2D separation strategy was required due to the complexity of the sample.
SEC was used to collect a Tf-containing fraction while a BDR column was used to deplete
the abundant serum albumin. Native MS was mandatory to preserve the metal and
synergistic anion composition of Tf which would be lost under denaturing conditions. One
of the six serum samples was observed to have oxalate as the synergistic anion instead of
the typical carbonate. Tf with bound oxalate is known to negatively affect iron homeostasis
as iron is unable to be released in cells. Current clinical tests can measure the amount of
oxalate in the blood but are unable to detect Tf-bound oxalate. The developed method has
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great potential to discover any potential link between oxalate-bound Tf and disruption to
iron homeostasis and its role in iron-related diseases.
Chapter III presented work on the glycan modification of a mAb and the effect on
its effector functions and biophysical properties. An IgG1 was enzymatically modified to
produce three different glycan-modified forms (deglycosylated, hypergalactosylated, and
hypersialylated). All three forms were characterized by various analytical methods for
comparison to each other and the unmodified IgG1. The goal of these experiments was to
understand how the glycan composition of a mAb affects its biophysical properties and
effector functions. Biophysical measurements did not reveal any significant changes
(excluding the loss of stability for the CH2 domain of deglycosylated IgG1 which has been
previously reported) in the higher order structure or stability of any of the three modified
IgGs. Removal of the glycan chain appears to abrogate any effector functions of IgG1
while maintaining its long half-life. If a mAb’s mechanism of action is drug delivery or
imagine, using a deglycosylated or aglycosylated mAb may be an attractive choice due to
its lack of effector function while maintaining a long half-life. Hypersialylation and
hypergalactosylation of an IgG1 were not shown to have a significant effect on half-lives
and effector functions. The lack of a significant effect allows for more variability of an
IgG1’s glycosylation composition during production without potentially affecting a mAb’s
in vivo function. An increase of terminal galactose(s) on a IgG1’s glycan chain is known
to correlate with a greater complement dependent cytotoxicity which might be attractive
for cancer targeting mAbs. Additionally, sialylated IgGs are known to possess antiinflammatory properties making its incorporation during production attractive for treating
inflammatory-related diseases. It is very important to establish how PTMs (glycosylation
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in this case) may affect the biophysical properties of a protein. If it can be determined that
PTMs will not affect a protein’s function or provide an alternative use for a biotherapeutic,
it provides more flexibility in producing a biotherapeutic.
A novel XP-RC/MS method was presented in chapter IV. A reagent plug is first
injected onto a column after which a protein sample is injected following a specified time
delay. At some point inside the column the two traveling peaks will cross and a chemical
reaction can take place. Due to SEC separating molecules by their hydrodynamic radius,
proteins will have a faster velocity than the reagent plug allowing them to be separated
during elution. Three proteins (β2m, IgG1, and Hp 1-1) were used to demonstrate the
versatility and usefulness of this approach. All three proteins were successfully reduced
on column using a TCEP-containing reagent plug. Each reduced protein was analyzed online by MS to confirm that reduction was successful. Reduction of Hp 1-1 allowed for
determining of the glycosylation of the heavy chain: such a determination is impossible at
the whole protein level due the heterogeneity of Hp 1-1. Specifically, the amount of
fucosylation of Hp 1-1 could be measured and is known to be relevant for certain disease
diagnoses. β2m and IgG1’s LC were both top-down sequenced by MS/MS after on column
reduction. XP-RC/MS is a powerful method as it allows for on column reduction of
disulfide containing proteins for MS and MS/MS analysis.
To further demonstrate the versatility of XP-RC/MS, a two reagent plug method
was implemented to first oxidize and then reduce IgG1. Eluting oxidized and reduced
species were detected on-line by MS to identify where oxidation is occurring on IgG1.
Based on measured mass shifts, only the HC was oxidized while the LC was unaffected.
A two reagent plug method suggests numerous possibilities in which a protein can be
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modified and then reduced. XP-RC/MS is a powerful tool for protein characterization that
greatly reduces sample analysis time and is suitable for proteins that are unstable after
reduction. The methods presented in this thesis demonstrate the wide range of usefulness
of LC- and MS-based methods for characterization of proteins with biotherapeutic
potential.

5.2

Future Directions

5.2.1

Quantitation of Iron Occupancy in Tf
The maximum concentration of iron that can be bound by serum Tf, from an

individual, is known as the total iron bound concentration (TIBC).1 TIBC is a colorimetric
assay that utilizes an iron binding molecule (chromazurol B) to measure free iron released
from Tf in solution. A TIBC measurement is used for a diagnosis of anemia, hereditary
hemochromatosis, and other iron deficiency disorders.1-3 However, TIBC does not provide
information with regard to the concentration of apo-, monoferric-, or holo-Tf in serum
which may be important to iron homeostasis in an individual. Holo-Tf binds to Tf receptor
(at pH 7.4) with the highest affinity followed by monoferric-Tf while apo-Tf has a very
weak affinity.4 Further information may be gathered by measuring the concentration or
percentage of apo-, monoferric-, or holo-Tf in a patient’s serum. It has been reported the
distribution of holo-Tf in is ~11 to 27%4 in serum. A plausible scenario of the importance
of being able to measure the concentrations of apo-, monoferric-, or holo-Tf is as follows.
Two patients are determined to have the same TIBC value but differ in their distribution of
monoferric- and holo-Tf which would not be detected by TIBC.
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Measuring the

concentration of monoferric- and holo-Tf could be useful when diagnosing iron related
diseases. Currently, urea gel analysis is used to estimate the different iron occupancy states
of Tf in serum.4 However this is not a high throughput assay that could be implemented
as a clinical test. Presented below is a method to measure the amount of apo-, monoferric, or holo-Tf in serum.
Figure 5.1 describes the general procedure for the purification of Tf from serum
and its analysis. First, serum is injected onto an SEC column and the eluting Tf fraction is
collected. To separate holo-Tf from apo- and monoferric-Tf a BDR column is used. As
show in figure 5.2, holo-Tf is not retained by the resin while monoferric- and apo-Tf are.
Separation of holo-Tf from apo- and monoferric-Tf allows for their concentrations to be
indirectly measured by a using chromazurol B. Free iron is bound by chromazurol B and
the concentration iron is calculated by measuring the 660nm absorbance and comparing it
to a calibration curve.

The general strategy to measure the concentration of apo-,

monoferric-, and holo-Tf involves the adjustment of the solution’s pH to promote Tf to
bind or release iron. Both Tf-containing fractions (holo-Tf and monoferric-/apo-Tf) are
first added to a low pH (4.5) solution with iron and chromazurol B. Released iron results
in the increased absorbance at 660 nm and is used to calculate the concentration of iron
bound by Tf. For the holo-Tf sample, the measured iron concentration is halved to
calculate holo-Tf’s concentration. The iron concentration for the monoferric-/apo-Tf
sample is equal to the concentration of monoferric-Tf. To determine the concentration of
apo-Tf, a neutral carbonate buffer (pH 7.0) is added to the low pH monoferric-/apo-Tf
solution. Raising the pH to near neutral permits Tf to bind iron and results in the decrease
of 660 nm absorbance. The concentration of iron bound is calculated by the decrease of
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660 nm absorbance and the concentration of Tf is equal to half of the measured iron
concentration. However, it is important to keep in mind that monoferric-Tf was converted
to apo-Tf in the previous step so the measured concentration of Tf is the combined
concentration of (previously) monoferric- and apo-Tf.

Subtracting monoferric-Tf’s

concentration from the total Tf concentration results in the concentration of apo-Tf.
Importantly, an automated plate reader with liquid transfer capabilities is able to handle the
chromazurol B absorbance detection making this assay to be high throughput.
It is the goal of this proposed method to accurately quantitate the amount of apo-,
monoferric-, or holo-Tf in serum. The generated data may help relate iron-related disease
symptoms with the iron occupancy of Tf. With this additional information, it may be
possible to establish additional biomarkers (such as % of holo-Tf or total concentration) to
assist with iron-related disease diagnosis.

5.2.2

Cross Path Reactive Chromatography
XP-RC/MS is a very versatile method due to the variety and number of plug that

can be employed. As shown in chapter IV, multiple plugs can be injected to facilitate
different protein reactions. This leads to the enticing possibility of performing online HDX
inside an SEC column. An HDX XP-RC/MS schematic is shown in figure 5.3. By
adjusting the time between plugs, a protein can be detected very quickly after exchange
and reduction. Furthermore unlike traditional HDX experiments there will be no dilution
(excluding diffusion of the protein plug inside the column) of the protein sample as it passes
through the deuterium plug. Additionally, the reduction plug can be removed if global
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HDX measurements are of interest. Reducing the time between exchange and detection
will help with back exchange that is major issue affecting current HDX measurements.
Other types of chromatography can be used for XP-RC/MS as long as the analyte
and reactive plugs can be separated. Ion exchange chromatography is a possible alternative
to SEC due to its ability to retain a molecule for significant amount of time under the correct
mobile phase conditions. By reversing the order of plugs in an SEC experiment, a protein
can first be injected followed by any number of reactive plugs, as shown in figure 5.4.
Once the reactive plugs elute from the column, a step gradient can be used to elute the
modified protein. This has the added benefit over SEC XP-RC/MS which has a limited
range of the number of plugs that can be effectively injected.

XP-RC/MS is a

compartmental method where different plugs or types chromatographies can be
implemented to tackle the unique requirements of an experiment.
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5.3

Figures

Figure 5.1 General schematic for quantitation of apo-, monoferric-, and holo-Tf. Serum
is injected onto an SEC column and a fraction containing Tf is collected. A BDR column
(cibacron F3GA) is used to separate holo-Tf from apo- and monoferric-Tf. Holo-Tf is
added to a low pH solution (4.5) containing iron and chromazurol B. The change in 660
nm absorbance is measured to calculate the concentration of holo-Tf. Apo- and
monoferric-Tf are added to a low pH solution (4.5) containing iron and chromazurol B.
The change in 660 nm absorbance is measured to calculate the concentration of
monoferric-Tf. Next, a carbonate buffer, pH 7.0, is added to the solution to allow Tf to
bind iron. The change in 660 nm absorbance is measured to calculate the concentration
of total Tf in solution. This concentration is subtracted by the previously measured
monoferric-Tf concentration to calculate the concentration of apo-Tf.

139

Figure 5.2 Separation of holo-Tf from monoferric- and apo-Tf on a cibacron F3GA
column using a salt gradient (red). The identity of Tf in each eluting peak was confirmed
by MS.
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Figure 5.3 Schematic for an online HDX assay inside an SEC column.

Figure 5.4 Representative workflow for an XP-RC-MS experiment in an IXC column.
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APPENDIX A
PURIFICATION AND ANALYSIS OF TF AND HUMAN SERUM ALBUMIN
FROM SERUM SAMPLES.
A.1 Introduction
Using the method developed in chapter II Tf was purified and measured from
several different serum samples. Additionally, human serum albumin (HSA) was also
measured by buffer exchanging HSA from the high salt fractions of the BDR runs into a
MS-friendly buffer. The objective was to determine the metal and synergistic anion
composition for Tf to determine if other Tf samples contained oxalate as the synergistic
anion. In addition, any PTMs of Tf and HSA were identified. Of particular interest was
the presence of glycation on Tf and HSA as it is a potential biomarker for diabetes
mellitus.1-3 Glycation has also been shown to negatively affect Tf’s ability bind iron thus
affect iron homeostasis in the body.4,5 Briefly, it was found at a physiologically relevant
time scale and glucose concentration Tf was able to be glycated at lysine534.4 Lysine534 is
a component of the secondary pH sensitive shell that is responsible for Tf’s ability to bind
and release iron. Glycation of lysine534 appears to disrupt Tf’s C-lobe to bind iron.
Therefore, it is important to determine if Tf is glycated as it may play a role in disrupting
iron homeostasis in the body.

A.2 Results and Discussion
All five HSA samples (Figures A.6-A.10) were observed to be modified by
glycation and cysteinylation. The relative abundance of glycation and cysteinylation for
each sample is different with respect to each other and unmodified HSA. Unfortunately,
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the health status of the serum sample patients is unknown. Consequently, no meaningful
correlation between glycation and or cysteinylation can be made to any ailments.
Of the five serum Tf samples two were observed with oxalate bound to iron. Also
observed was three of the Tf samples were glycated as shown in figures A.2-4.
Additionally, all five Tf samples appear to have different levels of apo-, monoferric-, and
holo-Tf. While it is tempting to make conclusions from the observed iron saturation and
synergistic anion composition, without the full medical history of the serum sample donors
this would be a imprudent decision. What can be discussed is out of the 7 (5 in this
appendix and 2 from the published paper) different Tf samples analyzed, three had oxalate
present as the synergistic anion. Moreover, three of the Tf samples were also observed to
be glycated. While this is a small sample set, oxalate bound to iron in Tf appears to be
common as well as glycation. To confirm this hypothesis and to attempt a link between
oxalate and glycation to iron related diseases, a large set of Tf samples would need to be
analyzed.
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A.1 Tf from serum was found to be bound to iron with carbonate and/or oxalate as its
synergistic anion. The black trace corresponds to native Tf and the red trace corresponds
to Tf at pH 3.7.
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A.2 Tf from serum was found to be bound to iron with carbonate as its synergistic anion.
Glycation of Tf was also observed. The black trace corresponds to native Tf and the red
trace corresponds to Tf at pH 3.7.

146

[(Fe3+CO32-).Tf]+20
Tf+20
100
90

+Glycation

relative intensity

80

[(Fe3+CO32-)2.Tf]+20

70
60
50
40
30
20
10
0
3940 3950 3960 3970 3980 3990 4000 4010 4020 4030 m/z

A.3 Tf from serum was found to be bound to iron with carbonate as its synergistic anion.
Glycation of Tf was also observed. The black trace corresponds to native Tf and the red
trace corresponds to Tf at pH 3.7.
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A.4 Tf from serum was found to be bound to iron with carbonate as its synergistic anion.
Glycation of Tf was also observed. The black trace corresponds to native Tf and the red
trace corresponds to Tf at pH 3.7.

148

[(Fe3+CO32-).Tf]+20
[(Fe3+ C2O42-).Tf ]+20

Tf+20

[(Fe3+2 CO32- C2O42-).Tf ]+20

100
90

relative intensity

80
70
60
50
40
30
20
10
0
3940 3950 3960 3970 3980 3990 4000 4010 4020 4030 m/z
A.5 Tf from serum was found to be bound to iron with carbonate and/or oxalate as its
synergistic anion. The black trace corresponds to native Tf and the red trace corresponds
to Tf at pH 3.7.
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A.6 Zoomed in mass spectrum of the +17-charge state of HSA. Peaks corresponding to
cysteinylation and glycation are labeled with a blue circle and red diamond respectively.
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A.7 Zoomed in mass spectrum of the +17-charge state of HSA. Peaks corresponding to
cysteinylation and glycation are labeled with a blue circle and red diamond respectively.
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A.8 Zoomed in mass spectrum of the +17-charge state of HSA. Peaks corresponding to
cysteinylation and glycation are labeled with a blue circle and red diamond respectively
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A.9 Zoomed in mass spectrum of the +17-charge state of HSA. Peaks corresponding to
cysteinylation and glycation are labeled with a blue circle and red diamond respectively
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A.10 Zoomed in mass spectrum of the +17-charge state of HSA. Peaks corresponding to
cysteinylation and glycation are labeled with a blue circle and red diamond respectively.
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APPENDIX B
CALCULATIONS AND SIMULATIONS FOR XP-RC-LC
B.1 Calculating the residency time of an analyte in the reactive plug
In order for XP-RC-LC to considered as a robust analytical technique additional
details about the interaction of the analyte and reactive plug as they cross paths is
required. One important detail is the time an analyte spends in the reagent plug which is
necessary for determining the reaction kinetics. Figure B.1 describes the relationship of
an analyte’s residency in the reactive plug to the difference in elution between analyte
and reactive plug. From the graph, it is clear the smaller difference between an analyte’s
and reactive plug’s elution time the more time they spend interacting which intuitively
makes sense. To calculate the time an analyte spends interacting (describe in detail vide
infra) with the reactive plug the reactive plug is treated as stationary to the analyte. This
can be modeled by subtracting the velocity of the analyte by the reactive plug to calculate
an adjusted analyte velocity. By dividing the volume of the reactive plug by the adjusted
analyte velocity, the time an analyte spends interacting with the reactive plug is
calculated. From this simple calculation, it is clearly seen that the time an analyte spends
interacting with the reactive plug can be easily controlled. One option is to change the
volume of the reactive plug while the other is to change the flow rate of mobile phase.
Both options allow for a great degree of control of the time an analyte interacts with the
reactive plug.
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Analyte residency time in the reactive plug calculation:
To calculate the analyte’s residency time in the reactive plug several values must be
experimentally determined.
(1) Column volume: Inject a small volume (20µL) of a 5% acetone solution onto the SEC
column. Calculate the elution time from the maximum of the eluting peak’s absorbance
(280nm). Multiply the elution time by the flow rate of the mobile phase to calculate the
column volume.
(2) Reactive plug’s velocity (vp): Assuming the reactive plug is composed of small
molecules far below the SEC column’s permeation limit and will not interact with the
stationary phase, the vp will be equal to the flow rate of the mobile phase.
(3) Analyte’s velocity (va): Inject a small volume of the analyte onto the SEC column.
Calculate the elution time from the maximum of the eluting peak’s absorbance (280nm).
Divide the column volume by the analyte’s retention time to calculate va.
(4) Analyte’s adjusted velocity (v’a): To calculate the analyte’s residency time in the
reactive plug, it will be treated as if the plug is stationary (as a point of reference) to the
analyte. The velocity of the analyte (va) will be subtracted by the velocity of the reactive
plug (vp) to calculate the adjusted velocity (v’a).
(5) Residency time in reactive plug: The volume of the reactive plug is divided by the
analyte’s adjusted velocity (v’a) to calculate the analyte’s time spent in the reactive plug.
*Note* Diffusion of the plug and analyte in the SEC column was not considered for these
calculations.
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B.1 The graph depicts the relationship of the difference of elution time for the analyte and
reactive plug to the amount of time an analyte spends in the reactive plug.
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B.2 Diffusion of reactive plug inside an SEC column
To further understand the reaction kinetics for XP-RC-LC the shape of the
reactive plug must be more fully defined. As the reactive plug travels through the SEC it
will diffuse longitudinally as described in the Van Deemter equation for chromatography.
This diffusion will lead to a concentration gradient that the analyte will interact with as it
passes through the reactive plug. To assess how shape of a plug changes as it travels
through an SEC column, a 300µL plug of 0.5% acetone was run at three different (100,
250, 500 µL/min) flow rates. For each flow rate a measurement was taken where the
UV/VIS detector was place pre- and post-SEC column as shown by figure B.2. When the
peaks from the respective flowrates are scaled and overlaid (figure B.3) it is clear there is
minimal longitudinal diffusion. Not surprisingly was the lowest flow rate (100µL/min)
had the most diffusion due to its increased time spent traveling through the column.
Also thought to be contributing to the band broadening is the introduction of the
plug to the SEC column. For all these experiments (and those performed in chapter IV) a
manual injector was used with a sample loop. The sample loop has a larger diameter than
the tubing coming from the pump and leading to the column. It is suspected as the
manual injector is turned and thus introducing the plug to the SEC column the mobile
phase is spiked through a portion of the reactive plug due to laminar flow. This would
create a mixture of mobile phase and reactive plug that will alter the concentration of the
active component(s) in the plug as well as lead to an increase of the plug’s volume. New
plumbing schemes will be needed to help minimize these issues to give a more uniform
reactive plug.
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B.2 UV/VIS detector placed before (top) and after (bottom) the SEC column.
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B.3 Overlay of the elution of the 0.5% acetone peak pre- (filled) and post- (outlined) SEC
column at the three different flow rates.
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